WO2017161269A1 - Inhibitors of ret receptor tyrosine kinases - Google Patents

Inhibitors of ret receptor tyrosine kinases Download PDF

Info

Publication number
WO2017161269A1
WO2017161269A1 PCT/US2017/022969 US2017022969W WO2017161269A1 WO 2017161269 A1 WO2017161269 A1 WO 2017161269A1 US 2017022969 W US2017022969 W US 2017022969W WO 2017161269 A1 WO2017161269 A1 WO 2017161269A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
ret
alkyl
hydrogen
subject
Prior art date
Application number
PCT/US2017/022969
Other languages
French (fr)
Inventor
Joseph L. Kim
Kevin J. Wilson
Joson D. BRUBAKER
Original Assignee
Blueprint Medicines Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corporation filed Critical Blueprint Medicines Corporation
Publication of WO2017161269A1 publication Critical patent/WO2017161269A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Definitions

  • adenocarcinoma and the RET-altered cell, cancer, gene, or gene product comprises KIF5B-RET (V804L).
  • the lung adenocarcinoma is NSCLC.
  • ring A is a 6-membered monocyclic heteroaryl comprising at least one nitrogen ring atom. In some embodiments, ring A
  • -Ci-C 4 alkyl is optionally substituted. In some embodiments, -Ci- C 4 alkyl is substituted. In some embodiments, -Ci-C 4 alkyl is unsubstituted.
  • R 12 is hydroxyl
  • Pharmaceutically acceptable salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium and the like, and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, besylate, acetate, maleate, oxalate and the like.
  • compositions of the invention comprise one or more compounds of the invention and one or more physiologically or pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier refers to a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof.
  • Each carrier must be “acceptable” in the sense of being compatible with the subject composition and its components and not injurious to the patient.
  • compositions of this invention may be orally
  • the subject has a cancer listed in Table 3, e.g. , the subject has both a RET mutation and a cancer listed in Table 3.
  • Amino acid position 8 Amino acid position 706 (e.g. , V706M or V706A)
  • Amino acid position 804 (e.g. , V804L, V804M,
  • Amino acid position 806 (e.g. , E806C, Y806E,
  • Amino acid position 510 (e.g. , A510V) Amino acid position 841 (e.g. , P841L or P841P) Amino acid position 511 (e.g. , E51 IK) Amino acid position 843 (e.g. , E843D)
  • Amino acid position 883 (e.g. , A883F, A883S,
  • Amino acid position 631 e.g. , D631N,
  • Amino acid position 1017 (e.g. , D1017N)
  • a substituted cycloalkyl iodide (either commercially available or prepared as described in "Synthesis of Iodide Intermediates") is treated with activated zinc.
  • the zinc could be activated by a variety methods, including but not limited to the method of Reike or treatment with TMS-Cl and 1,2-dibromoethane.
  • the cycloalkyl zinc reagent can then be coupled to a heteroaryl dihalide with palladium catalysis under Negishi coupling conditions.
  • the resulting carbon-carbon can form to give a mixture of diastereomers, which can be separated by chromatography or other separation techniques at this stage. Alternatively the diastereomers can be used as a mixture in the subsequent transformations and separated at a different stage.
  • Step 1 Synthesis of ethyl l-methoxy-3-(((trifluoromethyl)sulfonyl)oxy)cyclobutane-l- carboxylate
  • 7.5 nM - 10 nM of wild type RET (ProQinase 1090- 0000-1) is incubated in a total of 12.5 of buffer (100 mM HEPES pH 7.5, 0.015% Brij 35, 10 mM MgCl 2 , ImM DTT) with 1 ⁇ CSKtide (FITC - AHA- KKKKD DIYFFFG-NH2) (SEQ ID NO: 5) and 25 ⁇ ATP at 25°C for 120 minutes in the presence or absence of a dosed concentration series of compound (1% DMSO final concentration).
  • buffer 100 mM HEPES pH 7.5, 0.015% Brij 35, 10 mM MgCl 2 , ImM DTT
  • 1 ⁇ CSKtide FITC - AHA- KKKKD DIYFFFG-NH2
  • 7.5 nM - 10 nM of mutant RET (ProQinase 1096-0000- 1) is incubated in a total of 12.5 of buffer (100 mM HEPES pH 7.5, 0.015% Brij 35, 10 mM MgC12, ImM DTT) with 1 ⁇ CSKtide (FITC-AHA-KKKKDDIYFFFG-NH2) (SEQ ID NO: 5) and 10 ⁇ ATP at 25°C for 120 minutes in the presence or absence of a dosed concentration series of compound (1% DMSO final concentration).
  • buffer 100 mM HEPES pH 7.5, 0.015% Brij 35, 10 mM MgC12, ImM DTT
  • 1 ⁇ CSKtide FITC-AHA-KKKKDDIYFFFG-NH2
  • compounds according to structural Formula (I) and structural Formula (II) are potent and selective inhibitors of oncogenic RET mutant and fusion proteins. Currently, there are no approved inhibitors that selectively target these disease-driving RET alterations.
  • a compound described herein can be tested in vitro for inhibition of wild-type RET and various mutant RET kinases, including e.g., RET V804L, RET V804M, and RET M918T kinases, as well as CCDC6-RET and KIF5B-RET fusion kinases.
  • the IC50 can be calculated.
  • Antitumor efficacy of compounds of structural Formula (I) and (II) can be demonstrated in several RET-driven in vivo models.
  • the Ba/F3-KIF5B-RET allograft model uses KIF5B RET fusion-dependent Ba/F3 cells.
  • the test compound can be administered orally with an appropriate dose. Tumor size can be measured e.g., twice weekly.
  • administration of the compound results in robust and dose-dependent growth inhibition of Ba/F3-KIF5B-RET allograft tumors, e.g., in complete TGI and Mouse body weight can be measured e.g., twice- weekly during the administration.
  • the compound is well tolerated with no significant changes in animal body weight observed.
  • compounds according to structural Formula (I) and structural Formula (II) are potent inhibitors of wild-type and mutant RET.
  • the IC50 of a compound can be tested in a cell line comprising wild-type RET and in a second cell line comprising mutant RET, e.g., a point mutation or fusion.
  • compounds according to structural Formula (I) and structural Formula (II) are selective for RET over another kinase, such as KDR (also called Vascular endothelial growth factor receptor 2).
  • KDR is a tyrosine -protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD.
  • Inhibition of KDR/VEGFR2 has been associated clinically with certain adverse effects, e.g. , hypertension, arterial thrombosis, and hemorrhage, and therefore selectivity for RET over KDR is desirable.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Description

INHIBITORS OF RET RECEPTOR TYROSINE KINASES
This invention relates to inhibitors of RET that are active against wild-type RET and its resistant mutants.
CLAIM OF PRIORITY
This application claims priority from U.S. S.N. 62/309,748, filed March 17, 2016, which is incorporated herein in its entirety.
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on March 15, 2017, is named B2094-7022WO_SL.txt and is 32,316 bytes in size.
BACKGROUND
RET (rearranged during transfection) is a receptor tyrosine kinase that activates multiple downstream pathways involved in cell proliferation and survival. RET fusions are implicated in several cancers including papillary thyroid carcinoma and non-small cell lung cancer. A genomics analysis on the landscape of kinase fusions identified RET fusions in breast and colon cancer patient samples, providing therapeutic rationale for the use of RET inhibitors in multiple patient subpopulations.
The identification of RET fusions as drivers in some cancers prompted the use of approved multi-kinase inhibitors with RET inhibitory activity to treat patients whose tumors express a RET fusion protein. However, these drugs cannot always be dosed at the levels required to sufficiently inhibit RET due to toxicities that result from inhibition of targets other than RET. Further, one of the greatest challenges in treating cancer is the ability of tumor cells to become resistant to therapy. Kinase reactivation via mutation is a common mechanism of resistance. When resistance occurs, the patient's treatment options are often very limited, and the cancer progresses, unchecked, in most instances. There is thus a need for compounds that inhibit RET, as well as its resistant mutants. SUMMARY
The present invention provides inhibitors of RET and RET mutants, e.g. , RET resistant mutants (as defined herein), for example, inhibitors of structural Formula (I) and
pharmaceutically acceptable salts and compositions thereof. The present invention further provides methods of using the compounds of the invention, and pharmaceutically acceptable salts and compositions thereof, to inhibit the activity of RET or RET mutants in a cell or patient. The present invention still further provides methods for using the compounds of the invention, and pharmaceutically acceptable salts and compositions thereof, to treat a subject suffering from a condition mediated by aberrant RET activity, e.g. , cancer.
In one aspect, the invention features a compound of structural Formula (I) or a pharmaceutically acceptable salt thereof:
Figure imgf000003_0001
(I)
wherein each of ring A, X1, X2, R1, R2, R3a, R3b, R4, R5, R6, R7, R8a, R8b, R9, m and n is defined as described herein.
In another aspect, the present invention provides pharmaceutical compositions comprising a compound of structural Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
In another aspect, the present invention provides a method for inhibiting RET activity in a cell or in a patient. In some embodiments, said method comprises the step of contacting the cell or administering to the patient a compound of structural Formula (I) or a pharmaceutically acceptable salt or composition thereof. In some embodiments, the cell or patient has, or has been identified as having, a RET alteration, e.g. , a RET mutation, e.g. , a fusion or point mutation. In some embodiments, the patient comprises a RET-altered cell, cancer, gene, or gene product. In another aspect, the present invention provides a method for treating a subject suffering from a condition mediated by aberrant RET activity. In some embodiments, said method comprises administering to the subject a therapeutically effective amount of a compound of structural Formula (I) or a pharmaceutically acceptable salt or composition thereof. In some embodiments, the subject has or has been identified as having (e.g. , wherein a cancer cell in the subject has or has been identified as having) a RET alteration, e.g. , a RET mutation, e.g. , a fusion or point mutation. In some embodiments, a cell, cancer, gene, or gene product from the subject is or has been identified as being RET-altered. In some embodiments, the subject has or has been identified as having (e.g. , a cancer cell in the subject has or has been identified as having) a RET alteration, e.g. , a RET mutation, e.g. , a fusion or point mutation.
In some embodiments, the condition mediated by aberrant RET activity is a condition mediated by any RET activity that is not normal e.g. , any activity due to a RET-altered gene or gene product, which affects the amount or activity of the gene or gene product as compared to the normal or wild-type gene. In embodiments, the condition mediated by aberrant RET activity is a familial or sporadic cancer, e.g. , a solid tumor such as thyroid, lung, breast, or pancreatic. In embodiments, the condition mediated by aberrant RET activity is irritable bowel syndrome (IBS). In embodiments, the aberrant RET activity promotes the condition, such that inhibition of RET ameliorates at least one symptom of the condition. In embodiments, the aberrant RET activity comprises increased RET activity or expression level, gain of function mutation, and/or constitutive activation of RET. In embodiments, the aberrant RET activity corresponds to aberrant amounts of RET, e.g. , aberrant nucleic acid or protein amounts.
In another aspect, the present invention provides a method for treating a subject who has developed resistance to a cancer treatment. In some embodiments, said method comprises administering to the subject a therapeutically effective amount of a compound of structural Formula (I) or a pharmaceutically acceptable salt or composition thereof. In some embodiments, the subject has developed resistance to a wild-type RET inhibitor. In embodiments, the cancer treatment to which the subject is resistant is a wild-type RET inhibitor that is active against the wild-type RET, but less active, e.g. , much less active, against one or more mutated forms of RET. In some embodiments, the wild-type RET inhibitor is selected from ponatinib,
carbozanitib, and vandetanib. In another aspect, the present invention provides a use of a compound or pharmaceutical composition described herein, e.g. , a compound of structural Formula I, (la), (lb), II, (Ila), or (lib) described herein (e.g. , a compound in Table 1) or a pharmaceutically acceptable salt or composition thereof, in the manufacture of a medicament for inhibiting RET activity in a cell or in a subject. In embodiments, the cell or subject has, or has been identified as having, a RET alteration, e.g. , a RET mutation, e.g. , a fusion or point mutation. In embodiments, a cell, cancer, gene, or gene product from the subject is or has been identified as being RET-altered.
In another aspect, the present invention provides a use of a compound or pharmaceutical composition described herein, e.g. , a compound of structural Formula I, (la), (lb), II, (Ila), or (lib) described herein (e.g. , a compound in Table 1) or a pharmaceutically acceptable salt or composition thereof, in the manufacture of a medicament for treating a subject suffering from a condition mediated by aberrant RET activity. In embodiments, the subject has, or has been identified as having (e.g. , wherein a cancer cell in the subject has, or has been identified as having) a RET alteration, e.g. , a RET mutation, e.g. , a fusion or point mutation. In
embodiments, a cell, cancer, gene, or gene product from the subject is or has been identified as being RET-altered.
In another aspect, the present invention provides a use of a compound or pharmaceutical composition described herein, e.g. , a compound of structural Formula I, (la), (lb), II, (Ila), or (lib) described herein (e.g. , a compound in Table 1) or a pharmaceutically acceptable salt or composition thereof, in the manufacture of a medicament for treating a subject who has developed resistance to a cancer treatment.
In another aspect, the present invention provides a method of preventing development of one or more RET-altered cell, cancer, gene, or gene product, in a cell or in a patient, comprising the step of contacting the cell or administering to the patient a compound according to structural Formula (I).
In another aspect, the present invention provides a method of treating a subject suffering from cancer comprising the steps of:
a. receiving information related to a RET sequence, e.g. , information related to a RET- altered gene or gene product, e.g. , having a RET fusion or point mutation; and b. administering to the subject a compound described herein (e.g. , a compound having a lower IC50 for RET than for KDR, a compound having a similar IC50 for wild-type RET compared to mutant RET, and/or a compound of structural Formula I, (la), (lb), II, (Ila), or (lib) described herein (e.g. , a compound in Table 1)), or a pharmaceutical composition comprising the compound, if the information indicates a RET-altered cell, cancer, gene, or gene product.
In embodiments, the subject is administered a cancer treatment other than a compound of structural Formula (I) or (II) if the information indicates that the subject has a wild-type RET sequence. In embodiments, the cancer treatment is a wild-type RET inhibitor.
In another aspect, the present invention provides a method of treating cancer in a subject, said method comprising:
a. obtaining a biological sample (e.g. , a tumor biopsy) from a human subject;
b. detecting whether a RET-altered cell, cancer, gene, or gene product, e.g. , having a fusion or point mutation, is present in the biological sample;
c. identifying the subject as responsive to a compound described herein (e.g. , a compound having a lower IC50 for RET than for KDR, a compound having a similar IC50 for wild-type RET compared to mutant RET, and/or a compound of structural Formula I, (la), (lb), II, (Ha), or (lib) described herein (e.g. , a compound in Table 1)) when the presence of the RET- altered cell, cancer, gene, or gene product in the biological sample is detected; and
d. administering an effective amount of the compound to the subject.
In another aspect, the present invention provides a method of treating cancer in a subject, said method comprising:
a. determining if, having determined if, or receiving information that the subject has a RET-altered cell, cancer, gene, or gene product, e.g. , having a fusion or point mutation;
b. identifying the subject as responsive to a compound described herein (e.g. , a compound having a lower IC50 for RET than for KDR, a compound having a similar IC50 for wild-type RET compared to mutant RET, and/or a compound of structural Formula I, (la), (lb), II, (Ila), or (lib) described herein (e.g. , a
compound in Table 1)) when the subject has a RET-altered cell, cancer, gene, or gene product; and
c. administering an effective amount of the compound to the subject.
In another aspect, the present invention provides a method of diagnosing cancer in a subject, said method comprising:
a. obtaining a biological sample (e.g. , a tumor biopsy) from a human subject;
b. detecting whether a RET-altered cell, cancer, gene, or gene product, e.g. , having a fusion or point mutation, is present in the biological sample;
c. diagnosing the subject with cancer when the presence of the RET-altered cell, cancer, gene, or gene product in the biological sample is detected.
In another aspect, the present invention provides a method of predicting the efficacy of a compound described herein (a compound having a lower IC50 for RET than for KDR, a compound having a similar IC50 for wild-type RET compared to mutant RET, and/or a compound of structural Formula I, (la), (lb), II, (Ila), or (lib) described herein (e.g. , a compound in Table 1)) in a treatment of cancer in a subject comprising the step of:
determining if, having determined if, or receiving information that the subject has a RET-altered cell, cancer, gene, or gene product, e.g. , having a mutation, e.g. , a fusion or point mutation, e.g. , by a method selected from hybridization-based methods, amplification-based methods, microarray analysis, flow cytometry analysis, DNA sequencing, next-generation sequencing (NGS), primer extension, PCR, in situ hybridization, dot blot, and Southern blot; wherein said determining if, having determined if, or receiving information is predictive of efficacy of the compound in the treatment.
In some embodiments of any of the methods and uses herein, the method further comprises administering to the subject a compound described herein, e.g. , (e.g. , a compound having a lower IC50 for RET than for KDR, a compound having a similar IC50 for wild-type RET compared to mutant RET, and/or a compound of structural Formula I, (la), (lb), II, (Ila), or (lib) described herein (e.g. , a compound in Table 1)), e.g. , responsive to a determination or diagnosis made by a method described herein. In some embodiments of any of the methods and uses herein, the RET-altered cell, cancer, gene, or gene product comprises a fusion mutation, e.g. , CCDC6-RET or KIF5B-RET or a fusion of Table 3. In embodiments, the RET-altered cell, cancer, gene, or gene product comprises a point mutation of amino acid position 634, 918, or 804 of RET, or a point mutation at a position listed in Table 4, e.g. , a point mutation specified in Table 4. In some embodiments, the RET-altered cell, cancer, gene, or gene product comprises a point mutation at amino acid 634, 918, or 804, 806, 810, 865, 870, 891, e.g. , is selected from RET C634W, M918T, V804L, V804E, V804M, V804L, V806C, Y806C, Y806S, Y806N, Y806H, G810R, G810S, L865V, L870F, and S891A. In some embodiments, the RET alteration is located at least partially within, or is located wholly within one or more of: the N-terminal extracellular domain (e.g. , within one or more cadherin-like repeats and/or the cysteine-rich region), the transmembrane domain, or the tyrosine kinase domain (e.g. , within one or more of the ATP binding site or proton acceptor site). In some embodiments, the RET fusion further comprises a point mutation, e.g. , KIF5B-RET (V804L) or KIF5B-RET (V804M).
In some embodiments of any of the methods and uses herein, the subject suffers from a cancer selected from colorectal cancer, lung cancer (e.g. , a lung adenocarcinoma, e.g. , NSCLC), thyroid cancer (e.g. , medullary thyroid cancer), or leukemia. In embodiments, the subject suffers from a cancer listed herein, e.g. , in Table 3.
In some embodiments, the cancer is wild-type RET.
In some embodiments, the cancer is lung cancer, e.g. , a lung adenocarcinoma, and the RET-altered cell, cancer, gene, or gene product comprises a CCDC6-RET fusion. In some embodiments, the cancer is lung adenocarcinoma and the RET-altered cell, cancer, gene, or gene product comprises a KIF5B-RET fusion. In some embodiments, the cancer is lung
adenocarcinoma and the RET-altered cell, cancer, gene, or gene product comprises KIF5B-RET (V804L). In some embodiments, the lung adenocarcinoma is NSCLC.
In some embodiments, the cancer is thyroid cancer, e.g. , medullary thyroid cancer, and the RET-altered cell, cancer, gene, or gene product comprises a C634W mutation.
In some embodiments, the cancer is leukemia and the RET-altered cell, cancer, gene, or gene product comprises a KIF5B-RET fusion. In some embodiments, the cancer is thyroid cancer and the RET-altered cell, cancer, gene, or gene product comprises a M918T mutation. In some embodiments, the cancer is medullary thyroid cancer and the RET-altered cell, cancer, gene, or gene product comprises a M918T mutation.
In some embodiments, the cancer is leukemia and the RET-altered cell, cancer, gene, or gene product comprises comprises KIF5B-RET (V804L) or KIF5B-RET (V804M) fusion.
In some embodiments, the cancer is thyroid cancer and the RET-altered cell, cancer, gene, or gene product comprises comprises a CCDC6-RET fusion. In some embodiments, the cancer is colorectal cancer and the RET-altered cell, cancer, gene, or gene product comprises CCDC6-RET fusion. In some embodiments, the cancer is colorectal cancer and the RET-altered cell, cancer, gene, or gene product comprises CCDC6-RET (V804M) fusion.
In some embodiments of any of the methods and uses herein, the compound or pharmaceutical composition has a lower IC50 for RET than for KDR, e.g. , has a KDR/RET IC50 ratio of at least 3x, 4x, 5x, lOx, 20x, 50x, or lOOx, and optionally up to 50x or lOOx. In embodiments, the compound or pharmaceutical composition has a KDR/RET IC50 ratio of between 3x-4x, 4x-5x, 5x-10x, 10x-20x, 20x-50x, or 50x-100x. In some embodiments, the compound or pharmaceutical composition has a similar IC50 for wild-type RET compared to mutant RET (e.g. , for V804L RET or V804E RET), e.g. , has a wild-type/mutant IC50 ratio of no more than 3x, 2x, 1.5x, lx, or 0.5x, e.g. , of between 3x and 0.5x.
In some embodiments of any of the methods and uses herein, the subject does not develop a RET-altered cell, cancer, gene, or gene product for at least 1, 2, 3, 6, 9, 12, 24, or 36 months after initiation of administration of the compound. In some embodiments, the compound is administered as a first line therapy. In some embodiments, the compound is administered to a treatment-naive subject. In some embodiments, the compound is not administered in combination with another kinase inhibitor. In some embodiments, the compound is not administered in combination with another RET inhibitor. For example, the compound can be administered as a monotherapy or in combination with one or other agents which are not kinase inhibitors, e.g. , not RET inhibitors. In some embodiments of any of the methods and uses herein, the compound is administered at an amount sufficient to reach at least 70%, 80%, 90%, or 95% inhibition of RET in vivo.
EMBODIMENTS OF THE INVENTION
Definitions
As used herein, the terms a "patient," "subject," "individual," and "host" refer to either a human or a non-human animal suffering from or suspected of suffering from a disease or disorder associated with aberrant RET expression {i.e., increased RET activity caused by signaling through RET) or biological activity.
"Treat" and "treating" such a disease or disorder refers to ameliorating at least one symptom of the disease or disorder. These terms, when used in connection with a condition such as a cancer, refer to one or more of: impeding growth of the cancer, causing the cancer to shrink by weight or volume, extending the expected survival time of the patient, inhibiting tumor growth, reducing tumor mass, reducing size or number of metastatic lesions, inhibiting the development of new metastatic lesions, prolonging survival, prolonging progression- free survival, prolonging time to progression, and/or enhancing quality of life.
The term "therapeutic effect" refers to a beneficial local or systemic effect in animals, particularly mammals, and more particularly humans, caused by administration of a compound or composition of the invention. The phrase "therapeutically-effective amount" means that amount of a compound or composition of the invention that is effective to treat a disease or condition caused by over expression of RET or aberrant RET biological activity at a reasonable benefit/risk ratio. The therapeutically effective amount of such substance will vary depending upon the subject and disease or condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of skill in the art.
As used herein, "developing resistance" means that when a drug is first administered to the patient, the patient's symptoms improve, whether measured by decrease in tumor volume, a decrease in the number of new lesions, or some other means that a physician uses to judge disease progression; however, those symptoms stop improving, or even worsen at some point. At that time, the patient is said to have developed resistance to the drug.
"Alteration" as used herein, of a gene or gene product (e.g. , the RET gene or gene product) refers to the presence of a mutation or mutations within the gene or gene product, e.g. , a mutation, which of the gene or gene product, as compared to the normal or wild-type gene. The alteration can be in amount, structure, and/or activity in a cancer tissue or cancer cell, as compared to its amount, structure, and/or activity, in a normal or healthy tissue or cell (e.g. , a control), and is associated with a disease or condition, such as cancer. For example, an alteration which is associated with cancer, or predictive of responsiveness to an anti-cancer therapeutic, can have an altered nucleotide sequence (e.g. , a mutation), amino acid sequence, chromosomal translocation, intra-chromosomal inversion, copy number, expression level, protein level, protein activity, or methylation status, in a cancer tissue or cancer cell, as compared to a normal, healthy tissue or cell. Exemplary mutations include, but are not limited to, point mutations (e.g. , silent, missense, or nonsense), deletions, insertions, inversions, linking mutations, duplications, translocations, inter- and intra-chromosomal rearrangements. Mutations can be present in the coding or non-coding region of the gene, e.g. , a 3' UTR or 5' UTR.
A subject having "altered RET" refers to a subject comprising a RET alteration, e.g. , in one or more of their cancer cells.
A "RET-altered" cell, cancer, gene, or gene product refers to a cell, cancer, gene, or gene product comprising a RET alteration as described herein.
"Aliphatic group" means a straight-chain, branched-chain, or cyclic hydrocarbon group and includes saturated and unsaturated groups, such as an alkyl group, an alkenyl group, and an alkynyl group.
"Alkylene" refers to a divalent radical of an alkyl group, e.g. , -CH2-, -CH2CH2-, and -CH2CH2CH2-.
"Alkenyl" means an aliphatic group containing at least one double bond.
"Alkoxyl" or "alkoxy" means an alkyl group having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like. The term "haloalkoxy" refers to an alkoxy in which one or more hydrogen atoms are replaced by halo, and includes alkoxy moieties in which all hydrogens have been replaced by halo (e.g. , perfluoroalkoxy) .
"Alkyl" refers to a monovalent radical of a saturated straight or branched hydrocarbon, such as a straight or branched group of 1- 12, 1-10, or 1-6 carbon atoms, referred to herein as C1-C12 alkyl, C1-C10 alkyl, and Ci-C6 alkyl, respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-l -propyl, 2-methyl-2-propyl,
2- methyl-l -butyl, 3 -methyl- 1 -butyl, 2-methyl-3-butyl, 2,2-dimethyl-l -propyl, 2-methyl-l-pentyl,
3- methyl-l-pentyl, 4-methyl-l-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl- l -butyl, 3,3-dimethyl- l-butyl, 2-ethyl-l -butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, etc.
"Alkenylene" refers to an alkenyl group having two connecting points. For example, "ethenylene" represents the group -CH=CH-. Alkenylene groups can also be in an unsubstituted form or substituted form with one or more substituents.
"Alkynyl" refers to a straight or branched hydrocarbon chain containing 2- 12 carbon atoms and characterized in having one or more triple bonds. Examples of alkynyl groups include, but are not limited to, ethynyl, propargyl, and 3-hexynyl. One of the triple bond carbons may optionally be the point of attachment of the alkynyl substituent.
"Alkynylene" refers to an alkynyl having two connecting points. For example,
"ethynylene" represents the group -C≡C-. Alkynylene groups can also be in an unsubstituted form or substituted form with one or more substituents.
"Aromatic ring system" is art-recognized and refers to a monocyclic, bicyclic or polycyclic hydrocarbon ring system, wherein at least one ring is aromatic.
"Aryl" refers to a monovalent radical of an aromatic ring system. Representative aryl groups include fully aromatic ring systems, such as phenyl, naphthyl, and anthracenyl, and ring systems where an aromatic carbon ring is fused to one or more non-aromatic carbon rings, such as indanyl, phthalimidyl, naphthimidyl, or tetrahydronaphthyl, and the like.
"Arylene" refers to a divalent aryl, wherein "aryl" is as defined herein.
"Arylalkyl" or "aralkyl" refers to an alkyl moiety in which an alkyl hydrogen atom is replaced by an aryl group. Aralkyl includes groups in which more than one hydrogen atom has been replaced by an aryl group. Examples of "arylalkyl" or "aralkyl" include benzyl, 2- phenylethyl, 3-phenylpropyl, 9-fluorenyl, benzhydryl, and trityl groups.
"Aryloxy" refers to -O-(aryl), wherein the aryl moiety is as defined herein.
"Halo" refers to a radical of any halogen, e.g. , -F, -CI, -Br, or -I.
"Heteroalkyl" refers to an optionally substituted alkyl, which has one or more skeletal chain atoms selected from an atom other than carbon, e.g. , oxygen, nitrogen, sulfur, phosphorus or combinations thereof. A numerical range may be given, e.g. Ci-C6 heteroalkyl which refers to the number of carbons in the chain, which in this example includes 1 to 6 carbon atoms. For example, a -CH2OCH2CH3 radical is referred to as a "C3" heteroalkyl. Connection to the rest of the molecule may be through either a heteroatom or a carbon in the heteroalkyl chain.
"Heteroalkylene" refers to a divalent optionally substituted alkyl, which has one or more skeletal chain atoms selected from an atom other than carbon, e.g. , oxygen, nitrogen, sulfur, phosphorus or combinations thereof.
"Carbocyclic ring system" refers to a monocyclic, bicyclic or polycyclic hydrocarbon ring system, wherein each ring is either completely saturated or contains one or more units of unsaturation, but where no ring is aromatic.
"Carbocyclyl" refers to a monovalent radical of a carbocyclic ring system.
Representative carbocyclyl groups include cycloalkyl groups (e.g. , cyclobutyl, cyclopentyl, cyclohexyl and the like), and cycloalkenyl groups (e.g. , cyclopentenyl, cyclohexenyl,
cyclopentadienyl, and the like).
"Cycloalkyl" refers to a cyclic, bicyclic, tricyclic, or polycyclic non-aromatic
hydrocarbon groups having 3 to 12 carbons. Any substitutable ring atom can be substituted (e.g. , by one or more substituents). The cycloalkyl groups can contain fused or spiro rings. Fused rings are rings that share a common carbon atom. Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclohexyl, methylcyclohexyl, adamantyl, and norbornyl.
"Cycloalkylalkyl" refers to a -(cycloalkyl)-alkyl radical where cycloalkyl and alkyl are as disclosed herein. The "cycloalkylalkyl" is bonded to the parent molecular structure through the cycloalkyl group.
"Hetero aromatic ring system" is art-recognized and refers to monocyclic, bicyclic or polycyclic ring system wherein at least one ring is both aromatic and comprises at least one heteroatom (e.g. , N, O or S); and wherein no other rings are heterocyclyl (as defined below). In certain instances, a ring which is aromatic and comprises a heteroatom contains 1, 2, 3, or 4 ring heteroatoms in such ring.
"Heteroaryl" refers to a monovalent radical of a heteroaromatic ring system.
Representative heteroaryl groups include ring systems where (i) each ring comprises a heteroatom and is aromatic, e.g. , imidazolyl, oxazolyl, thiazolyl, triazolyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl; (ii) each ring is aromatic or carbocyclyl, at least one aromatic ring comprises a heteroatom and at least one other ring is a hydrocarbon ring or e.g. , indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl,
benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, pyrido[2,3-b]- l,4-oxazin-3- (4H)-one, 5,6,7, 8-tetrahydroquinolinyl and 5,6,7,8-tetrahydroisoquinolinyl; and (iii) each ring is aromatic or carbocyclyl, and at least one aromatic ring shares a bridgehead heteroatom with another aromatic ring, e.g. , 4H-quinolizinyl.
"Heteroarylene" refers to a divalent heteroaryl, wherein "heteroaryl" is as defined herein.
"Heterocyclic ring system" refers to monocyclic, bicyclic and polycyclic ring systems where at least one ring is saturated or partially unsaturated (but not aromatic) and that ring comprises at least one heteroatom. A heterocyclic ring system can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
"Heterocyclyl" refers to a monovalent radical of a heterocyclic ring system.
Representative heterocyclyls include ring systems in which (i) every ring is non-aromatic and at least one ring comprises a heteroatom, e.g. , tetrahydro furanyl, tetrahydropyranyl,
tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl; (ii) at least one ring is non-aromatic and comprises a heteroatom and at least one other ring is an aromatic carbon ring, e.g. , 1,2,3,4-tetrahydroquinolinyl,
1,2,3,4-tetrahydroisoquinolinyl; and (iii) at least one ring is non-aromatic and comprises a heteroatom and at least one other ring is aromatic and comprises a heteroatom, e.g. , 3,4-dihydro- lH-pyrano[4,3-c]pyridine, and l,2,3,4-tetrahydro-2,6-naphthyridine.
"Heterocyclylalkyl" refers to an alkyl group substituted with a heterocyclyl group.
"Cyano" refers to a -CN radical.
"Nitro" refers to -N02.
"Hydroxy" or "hydroxyl" refers to -OH.
Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention. Thus, when a disclosed compound is named or depicted by a structure without specifying the stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound, as well as enantiomeric mixtures thereof. When a disclosed compound is named or depicted by a structure specifying stereochemistry at each chiral center, it is understood to represent only the compound having the designated stereochemistry at such chiral centers. However, when a disclosed compound specifies stereochemistry at some, but not all chiral centers, it is understood to represent all possible stereoisomers at the non-specified chiral centers of the compound, as well as enantiomeric mixtures thereof.
If, for instance, a particular enantiomer of compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.
The "enantiomeric excess" or "% enantiomeric excess" of a composition can be calculated using the equation shown below. In the example shown below a composition contains 90% of one enantiomer, e.g., the S enantiomer, and 10% of the other enantiomer, i.e., the R enantiomer.
ee = (90-10)/100 = 80%.
Thus, a composition containing 90% of one enantiomer and 10% of the other enantiomer is said to have an enantiomeric excess of 80%.
The compounds or compositions described herein may contain an enantiomeric excess of at least 50%, 75%, 90%, 95%, or 99% of one form of the compound, e.g., the S-enantiomer. In other words such compounds or compositions contain an enantiomeric excess of the S enantiomer over the R enantiomer.
The compounds described herein may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example deuterium ( H), tritium ( 3 H), carbon- 13 ( 13 C), or carbon- 14 ( 14 C). All isotopic variations of the compounds disclosed herein, whether radioactive or not, are intended to be encompassed within the scope of the present invention. In addition, all tautomeric forms of the compounds described herein are intended to be within the scope of the invention.
The compound can be useful as the free base or as a salt. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. (See, for example, Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66: 1- 19.)
As described herein, compounds of the invention may contain "optionally substituted" moieties. In general, the term "substituted", whether preceded by the term "optionally" or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at each position. Combinations of substituents envisioned under this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable", as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
Suitable substituents for an optionally substituted alkyl, alkylene, heteroalkyl, heteroalkylene, carbocyclyl, heterocyclyl, aryl group and heteroaryl group include halogen, =0, - CN, -ORc, -NRdRe, -S(0)kRc, -NRcS(0)2Rc, -S(0)2NRdRe, -C(=0)ORc, -OC(=0)ORc,- OC(=0)Rc, -OC(=S)ORc, -C(=S)ORc, -0(C=S)Rc, -C(=0)NRdRe, -NRcC(=0)Rc, -C(=S)NRdRe, -NRCC(=S)RC, -NRc(C=0)ORc, -0(C=0)NRdRe, -NRc(C=S)ORc, -0(C=S)NRdRe, -NRc(C=0)NRdRe, -NR c(C=S)NRdRe, -C(=S)RC, -C(=0)Rc, C C6 alkyl, d-C6 haloalkyl, Q-Q heteroalkyl, carbocyclyl, (C C6- alkylene)-carbocyclyl, (Ci-C6-heteroalkylene)-carbocyclyl, heterocyclyl, (Ci-C6-alkylene)-heterocyclyl, (Ci-C6-heteroalkylene)-heterocyclyl, aryl, (Ci-C6-alkylene)-aryl, (Ci-C6-heteroalkylene)-aryl, heteroaryl, (Ci-C6-alkylene)-heteroaryl, or (Ci-C6-heteroalkylene)-heteroaryl, wherein each of said alkyl, alkylene, heteroalkyl, heteroalkylene, carbocyclyl, heterocyclyl, aryl and heteroaryl are optionally substituted with one or more of halogen,
ORc, -N02, -CN, -NRcC(=0)Rc, -NRdRe, -S(0)kRc, -C(=0)ORc, -C(=0)NRdRe, -C(=0)Rc, C C6 alkyl, C C6 haloalkyl, or C C6 heteroalkyl, and wherein Rc is hydrogen, hydroxy, C C6 alkyl, C C6 heteroalkyl, carbocyclyl, (Q-Ce-alkylene^carbocyclyl, (Q-Ce-heteroalkylene^carbocyclyl, heterocyclyl, (Q-Ce-alkylene^heterocyclyl, (Q-Ce-heteroalkylene^heterocyclyl, aryl, (Q-Ce-alkylene^aryl, (C C6- heteroalkylene)-aryl, heteroaryl, (Q-Ce-alkylene^heteroaryl, or (Q-Ce-heteroalkylene^heteroaryl, each of which is optionally substituted with one or more of halogen, hydroxy, C C6 alkyl, C C6 haloalkyl, Q- C6 heteroalkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl; Rd and Re are each independently selected from hydrogen, C C6 alkyl, or C C6 heteroalkyl; and k is 0, 1 or 2. The invention is not intended to be limited in any manner by the above exemplary listing of substituents.
Compounds
In one aspect, the present invention features a compound having the structural Formula
(I):
Figure imgf000018_0001
(I) or a pharmaceutically acceptable salt thereof, wherein: ring A is an aryl or heteroaryl ring;
each of X1 and X2 is independently selected from N and C(R6);
1 7
each R and each R is independently selected from selected from Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-C6 alkoxy, halo, Ci-C6 heteroalkyl, cycloalkyl, aryl, heteroaryl, aryloxy, aralkyl, heterocyclyl, heterocyclylalkyl, nitro, cyano, -C(0)R, -OC(0)R, - C(0)OR, -(Ci-C6 alkylene)-C(0)R, -SR, -S(0)2R, -S(0)2-N(R)(R), -(Ci-C6 alkylene)- S(0)2R, -(Ci-C6 alkylene)-S(0)2-N(R)(R), -N(R)(R), -C(0)-N(R)(R), -N(R)-C(0)R, -N(R)- C(0)OR, -(Ci-C6 alkylene)-N(R)-C(0)R, -N(R)S(0)2R, and -P(0)(R)(R); wherein each of alkyl, alkenyl, alkynyl, alkoxy, heteroalkyl, cycloalkyl, aryl, heteroaryl, aryloxy, aralkyl, heterocyclyl, and heterocyclylalkyl is independently substituted with 0-5 occurrences of Ra; or two R1 or two R are taken together with the carbon atoms to which they are attached form a cycloalkyl or heterocyclyl ring independently substituted with 0-5 occurrences of Rb;
each of R2, R3a, R3b, R4, R8a and R8b is independently selected from hydrogen, Ci-C6 alkyl, Ci-C6 alkoxy, halo, hydroxyl, Ci-C6 heteroalkyl, and -N(R)(R); wherein each alkyl, alkoxy, and heteroalkyl is optionally and independently substituted with 0-5 occurrences of Ra; each of R5 and R9 is independently selected from hydrogen, Ci-C6 alkyl, and Ci-C6 heteroalkyl; wherein each alkyl and heteroalkyl is optionally and independently substituted with 0-5 occurrences of Ra;
each R6 is independently selected from hydrogen, Ci-C6 alkyl, Ci-C6 alkoxy, halo, Ci-C6 heteroalkyl, and -N(R)(R); wherein each alkyl, alkoxy, and heteroalkyl is optionally and independently substituted with 0-5 occurrences of Ra;
each R is independently selected from hydrogen, hydroxyl, halo, thiol, Ci-C6 alkyl, Ci-C6 thioalkyl, Ci-C6 alkoxy, Ci-C6 heteroalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, wherein each of alkyl, thioalkyl, alkoxy, heteroalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl is independently substituted with 0-5 occurrences of Ra, or two R together with the atom(s) to which they are attached form a cycloalkyl or heterocyclyl ring independently substituted with 0-5 occurrences of
Rb;
each Ra and each Rb is independently selected from Ci-C6 alkyl, halo, hydroxyl, Ci-C6 heteroalkyl, Ci-C6 alkoxy, cycloalkyl, heterocyclyl, or cyano, wherein each of alkyl, heteroalkyl, alkoxy, cycloalkyl and heterocyclyl is independently substituted with 0-5 occurrences of R'; each R' is independently selected from Ci-C6 alkyl, Ci-C6 heteroalkyl, halo, hydroxyl, cycloalkyl or cyano; or two R together with the atom(s) to which they are attached form a cycloalkyl or heterocyclyl ring;
m is 0, 1, or 2; and
n is 0, 1, 2, or 3.
In some embodiments, the compound has structural Formula (la):
Figure imgf000019_0001
(la) or a pharmaceutically acceptable salt thereof,
wherein ring A, X1, X2, R1, R2, R3a, R3b, R4, R5, R6, R7, R8a, R8b, R9, m and n are as defined as for structural Formula (I).
In some embodiments, the compound has structural Formula (lb):
Figure imgf000020_0001
(lb) or a pharmaceutically acceptable salt thereof,
wherein ring A, X1, X2, R1, R2, R3a, R3b, R4, R5, R6, R7, R8a, R8b, R9, m and n are as defined as for structural Formula (I).
In some embodiments of any of structural Formula I, (la) or (lb), R1 is located at the 5- position. In some embodiments, R1 is Ci-C4 alkyl optionally substituted with 0-3 occurrences of Ra. In some embodiments, m is 1 or 2. In some embodiments, m is 1. In some embodiments, m is 1; R1 is located at the 5-position; and R1 is Ci-C4 alkyl optionally substituted with 0-3 occurrences of Ra. In some embodiments, R1 is -CH3.
In some embodiments of any of structural Formula I or (la), R is selected from hydrogen, hydroxyl, halo and 0-Ci-C4 alkyl. In some embodiments, R is selected from hydrogen, hydroxyl, fluoro, and -OCH3.
In some embodiments of any of structural Formula I, (la) or (lb), each of R3a, R3b, R8a and
R 8b is independently selected from hydrogen and Ci-C4 alkyl optionally substituted with 0-3 occurrences of Ra. In some embodiments, each of R3a, R3b, R8a and R8b is independently selected from hydrogen and -CH3. In some embodiments, at least one pair of R3a and R3b or R8a and R8b is simultaneously hydrogen. In some embodiments, each of R3a, R3b, R8a and R8b is hydrogen.
In some embodiments of any of structural Formula I, (la) or (lb), R4 is selected from hydrogen, Ci-C4 alkyl, and 0-Ci-C4 alkyl, wherein each alkyl portion of R4 is optionally substituted with 0-3 occurrences of Ra. In some embodiments, R4 is selected from
hydrogen, -CH3 and -OCH3.
In some embodiments of any of structural Formula I, (la) or (lb), R5 is selected from hydrogen and Ci-C4 alkyl optionally substituted with 0-3 occurrences of Ra. In some
embodiments, R5 is selected from hydrogen and -CH3. In some embodiments of any of structural Formula I, (la) or (lb), each R6 is independently selected from hydrogen, halo, and Ci-C4 alkyl substituted with 0-3 occurrences of Ra. In some embodiments of any of structural Formulae I, (la) or (lb), R6 is selected from hydrogen and Ci-C4 alkyl optionally substituted with 0-3 occurrences of Ra. In some
embodiments, each R6 is independently selected from hydrogen, chloro and -CH3. In some embodiments, each R6 is independently selected from hydrogen and -CH3. In some
embodiments, no more than one R6 is other than hydrogen.
In some embodiments of any of structural Formula I, (la) or (lb), ring A is a 6-membered monocyclic heteroaryl comprising at least one nitrogen ring atom. In some embodiments, ring A
Figure imgf000021_0001
is pyridine or pyrazine. In some embodiments, ring A is selected from and
Figure imgf000021_0002
n
In some embodiments of any of structural Formula I, (la) or (lb), R is heteroaryl optionally substituted with 0-3 occurrences of Rb. In some embodiments, R is a 5-membered monocyclic heteroaryl optionally substituted with 0-3 occurrences of Rb. In some embodiments, R is a 5-membered monocyclic nitrogen-containing heteroaryl (e.g. , a 5-membered monocyclic heteroaryl comprising 1 or 2 nitrogen atoms) optionally substituted with 0-3 occurrences of Rb. In some embodiments, R7 is pyrazol-l-yl optionally substituted with 0-3 occurrences of Rb. In some embodiments, n is 1. In some embodiments, n is 1 ; and R is pyrazol-l-yl optionally substituted with 0-3 occurrences of Rb. In some embodiments, R7 is 4-fluoropyrazol- l-yl.
In some embodiments of any of structural Formula I, (la) or (lb), R9 is selected from hydrogen and Ci-C4 alkyl optionally substituted with 0-3 occurrences of Ra. In some
embodiments, R9 is hydrogen. In some embodiments, R9 is Q-C4 alkyl. In some embodiments, R5 and R9 are both hydrogen.
In another aspect, the present invention features a compound having the structural structural Formula (II):
Figure imgf000022_0001
(II), or a pharmaceutically acceptable salt thereof, wherein:
X1 is selected from N, CH and C(halo);
X is selected from N and CH;
X is selected from N and CH;
R 12 is selected from hydrogen, hydroxyl, halo and 0-Ci-C4 alkyl;
R14 is selected from hydrogen, -Ci-C4 alkyl and -0-Ci-C4 alkyl;
R15 is selected from hydrogen and -Ci-C4 alkyl;
R16 is selected from hydrogen and -Ci-C4 alkyl;
R 17 is selected from hydrogen and halo; and
R19 is selected from hydrogen and -Ci-C4 alkyl.
In some embodiments, -Ci-C4 alkyl is optionally substituted. In some embodiments, -Ci- C4 alkyl is substituted. In some embodiments, -Ci-C4 alkyl is unsubstituted.
In an embodiment, X1 is N and R16 is -C¾.
is a compound having the structural Formula (Ila):
Figure imgf000022_0002
r a pharmaceutically acceptable salt thereof, wherein X1, X2, X3, R12, R14, R15, R17, R16 and R19 are as defined as for structural Formula (II). , the compound is a compound having the structural Formula (lib):
Figure imgf000023_0001
(lib) or a pharmaceutically acceptable salt thereof,
wherein X1, X2, X3, R12, R14, R15, R17, R16 and R19 are as defined as for structural Formula (II).
In some embodiments of any of structural Formula II, (Ila) or (lib), X1 is N or CH. In some embodiments, X1 is N.
In some embodiments of any of structural Formula II, (Ila) or (lib), X is N or CH.
In some embodiments of any of structural Formula II, (Ila) or (lib), X is N. In some embodiments of any of Formula II, (Ila) or (lib), X3 is CH.
In some embodiments of any of structural Formula II, (Ila) or (lib), R 12 is selected from hydrogen, hydroxyl, fluoro and iments, R 12
-OCH3. In some embod is hydrogen. In some embodiments, R 12 is hydroxyl.
In some embodiments of any of structural Formula II, (Ila) or (lib), R14 is selected from hydrogen, -CH3 and -OCH3. In some embodiments, R14 is hydrogen. In some embodiments, R14 is -CH3.
In some embodiments of any of structural Formula II, (Ila) or (lib), R 12 is selected from hydrogen and hydroxyl; and R14 is selected from hydrogen, -CH3 and -OCH3. In some embodiments, R12 and R14 are both hydrogen.
In some embodiments of any of structural Formula II, (Ila) or (lib), R15 is H or -CH3.
In some embodiments of any of structural Formula II, (Ila) or (lib), R16 is selected from hydrogen and -CH3. In some embodiments, when X1 is CH, R16 is -CH3.
In some embodiments of any of structural Formula II, (Ila) or (lib), X1 is N and R16 is -
CH3. In some embodiments of any of structural Formula II, (Ila) or (lib), R is selected from
17 17 hydrogen and fluoro. In some embodiments, R is hydrogen. In some embodiments, R is fluoro.
In some embodiments of any of structural Formula II, (Ila) or (lib), R19 is H or -CH3. In some embodiments, R19 is H.
In some embodiments, the present invention features a compound selected from any compound in Table 1.
In another aspect, the present invention features a pharmaceutical composition
comprising a compound of structural Formula I, (la), (lb), II, (Ila), or (lib) described herein (e.g. , a compound in Table 1) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
In another aspect, the present invention features a method for inhibiting RET activity in a cell or in a patient comprising the step of contacting the cell or administering to the patient a compound described herein (e.g. , a compound in Table 1) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
In another aspect, the present invention features a method for treating a subject suffering from a condition mediated by aberrant RET activity, comprising administering to the subject a therapeutically effective amount of a compound described herein (e.g. , a compound in Table 1) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
In another aspect, the present invention features a method for treating a subject who has developed resistance to a cancer treatment, comprising administering to the subject a
therapeutically effective amount of a compound described herein (e.g. , a compound in Table 1) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some embodiments, the subject has developed resistance to a wild-type RET inhibitor.
Table 1. Exemplary Compounds of the Invention.
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Pharmaceutically acceptable salts of these compounds are also contemplated for the uses described herein.
"Pharmaceutically acceptable salt" refers to any salt of a compound of the invention whic retains its biological properties and which is not toxic or otherwise undesirable for pharmaceutical use. Pharmaceutically acceptable salts may be derived from a variety of organic and inorganic counter-ions well known in the art and include. Such salts include: (1) acid addition salts formed with organic or inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, sulfamic, acetic, trifluoroacetic, trichloroacetic, propionic, hexanoic, cyclopentylpropionic, glycolic, glutaric, pyruvic, lactic, malonic, succinic, sorbic, ascorbic, malic, maleic, fumaric, tartaric, citric, benzoic, 3-(4-hydroxybenzoyl)benzoic, picric, cinnamic, mandelic, phthalic, lauric, methanesulfonic, ethanesulfonic, 1 ,2-etliane-disulfonic, 2- hydroxyethanesulfonic, benzenesulfonic, 4-chlorobenzenesulfonic, 2-naphthalenesulfonic, 4- toluenesulfonic, camphoric, camphorsulfonic, 4-methylbicyclo[2.2.2]-oct-2-ene-l -carboxylic, glucohep onic, 3-phenylpropionic, trimethylacetic, tert-butylacetic, lauryl sulfuric, gluconic, benzoic, glutamic, hydroxynaphthoic, salicylic, stearic, cyclohexylsuifamic, quinic, muconic acid and the like acids; or (2) salts formed when an acidic proton present in the parent compound either (a) is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion or an aluminum ion, or alkali metal or alkaline earth metal hydroxides, such as sodium, potassium, calcium, magnesium, aluminum, lithium, zinc, and barium hydroxide, ammonia or (b) coordinates with an organic base, such as aliphatic, alicyclic, or aromatic organic amines, such as ammonia, methylamine, dime thy lamine, diethylamine, picoline, ethanolamine, diethanolamine, triethanolamine, ethylenedianiine, lysine, arginine, ornithine, choline, N,N'-dibenzylethyl.ene- diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, N- methylglucamine piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, and the like. Pharmaceutically acceptable salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium and the like, and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, besylate, acetate, maleate, oxalate and the like.
Pharmaceutical Compositions
Pharmaceutical compositions of the invention comprise one or more compounds of the invention and one or more physiologically or pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof. Each carrier must be "acceptable" in the sense of being compatible with the subject composition and its components and not injurious to the patient. Some examples of materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.
The compositions of the invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra- articular, intra- synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. In some embodiments, the compositions of the invention are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.
For this purpose, any bland fixed oil may be employed including synthetic mono- or di- glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tween, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
The pharmaceutically acceptable compositions of this invention may be orally
administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
Alternatively, the pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
The pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs. Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
For topical applications, the pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
The pharmaceutically acceptable compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well- known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
The amount of the compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration.
Dosages
Toxicity and therapeutic efficacy of compounds of the invention, including
pharmaceutically acceptable salts and deuterated variants, can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The LD50 is the dose lethal to 50% of the population. The ED50 is the dose therapeutically effective in 50% of the population. The dose ratio between toxic and therapeutic effects (LD50/ ED50) is the therapeutic index. Compounds that exhibit large therapeutic indexes are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
Data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds may lie within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.
Treatment
RET fusions have been implicated in several types of cancers. Generally, these RET fusions have a RET kinase domain that is the same as in wild-type RET; therefore, as used herein, any RET protein with the same kinase domain as wild-type RET will be referred to as "wild-type RET" unless noted otherwise. Mutations can occur at least in the RET extracellular and kinase domains. Mutations can occur in the RET kinase domain, leading to resistant mutants of RET.
The activity of exemplary compounds that are approved or in development for RET- related conditions is shown below. As shown, the compounds are active against the wild-type RET, but are much less active against the mutated forms ("wild-type RET inhibitors").
Table 2.
Figure imgf000034_0001
The invention provides compounds that inhibit both wild-type RET and mutants of RET, ., mutants of RET that are resistant to current standard of care treatments ("RET resistant mutants"). In addition, the compounds of the invention can be selective for wild-type RET, over other kinases, thus leading to reduced toxicities associated with inhibiting other kinases. In one aspect, compounds of the invention are selective for RET over KDR. In one aspect, compounds of the invention do not cause adverse effects such as hypertension, arterial thrombosis, and hemorrhage.
Mutations can be predicted using structural biology and computational analyses, as well as by examining codon sequences in which a sequence change gives rise to a codon for a different amino acid. Using such methods, RET resistant mutants are predicted to have point mutations at the 804 gatekeeper residue in the RET protein and/or at residues at or near the gatekeeper residue. In some embodiments, the mutation may be at one or more of the 804, 806, 810, 865, 870, 891, and 918 residues. Specific examples of RET resistant mutants include: V804L, V804M, V804E, Y806C, Y806S, Y806H, Y806N, G810R, G810S, L865V, L870F, S891A and M918T mutants.
Mutations occurring from administration of a particular inhibitor (e.g. , a known RET wild-type inhibitor) can be determined experimentally by exposing cells to a mutation-promoting agent, such as ENU. The cells are washed, then plated with increasing concentrations (2- 100X proliferation IC50) of the compound of choice. The wells with cellular outgrowth are then collected after 3-4 weeks. The RET kinase domain is then sequenced to identify resistance mutations (i.e. , altered forms of the RET protein that retain enzymatic activity). Resistance can be confirmed by exposing these cells with the compound of choice. Resistant mutants that have been identified experimentally include the V804L, V804E, V804M, and Y806H mutants. In some embodiments, the mutation is a substitution of cysteine (C609, C611, C618, C620, C630, and C634) in the RET extracellular domain for any other amino acid. In some embodiments, the RET cysteine variants (affecting C609, C611, C618, and C620) are the "Janus mutations." In some embodiments, RET mutations include: RET C634W, RET M918T, V804L, V804E, V804M, V804L, Y806C, Y806S, Y806N, Y806H, G810R, G810S, L865V, L870F, and S891A mutants.
Because of their activity against wild-type RET and mutant RET, the compounds described herein can be used to treat a patient with a condition associated with aberrant RET activity. The compounds described herein can provide treatments for irritable bowel syndrome (IBS), proliferative diseases, and any other conditions related to aberant RET activity. The compounds can be used to treat irritable bowel syndrome. The compounds can be used to treat various cancers. In some embodiments, the cancer is selected from papillary thyroid carcinoma (PTC), medullary thyroid cancer (MTC), pheochromocytoma (PC), pancreatic ductal adenocarcinoma, multiple endocrine neoplasia (MEN2A and MEN2B), metastatic breast cancer, testicular cancer, small cell lung cancer, non-small cell lung cancer, chronic myelomonocytic leukemia, colorectal cancer, ovarian cancer, and cancers of the salivary gland. In some embodiments, the cancer is a solid tumor. In some embodiments, the condition associated with aberrant RET activity is a thyroid cancer (e.g. , papillary thyroid carcinoma, thyroid
adenocarcinoma, or MTC, e.g. , familial MTC), lung cancer (e.g. , lung adenocarcinoma, small- cell lung carcinoma, or non-small cell lung carcinoma), breast cancer (e.g. , estrogen receptor- positive tumors and endocrine-resistant tumors e.g. , resistant to oestrogen modulators such as tamoxifen, agents that block oestrogen biosynthesis such as aromatase inhibitors, and oestrogen receptor antagonists such as fulvestrant), pancreatic cancer (e.g. , carcinoma of the pancreas or pancreatic ductal carcinoma), haematopoietic cancer, e.g. , a leukemia (e.g. , chronic
myelomonocytic leukemia or acute myeloid leukemia), colon cancer (e.g. , colon carcinoma), melanoma (e.g. , cutaneous or desmoplastic malignant melanomas), prostate cancer, renal cancer (e.g. , renal cell carcinoma), and head and neck tumors, neuroblastoma, ganglioneuroma (e.g. , ganglioneuroma of the mouth or gut), colon cancer (e.g. , sporadic colon cancers), MEN2A (multiple endocrine neoplasia type 2A), or MEN2B (multiple endocrine neoplasia type 2B). In one aspect, the MEN2A is characterized by MTC and includes adrenal tumor
pheochromocytoma. Substitutions of cysteines in RET are found in subjects with MEN2A and also frequent in FMTC. RET extracellular domain exon 8 mutations, such as G533C) or the RET intracellular domain (residues E768, L790, Y791, V804, and S891) are associated with FMTC or MEN2A. Substitutions in the RET kinase domain, Met918 to Thr (M918T) or A883F are found in subjects with MEN2B. RET M918T and RET A883F are also found in sporadic MTC.
The compounds can also be used to treat a patient who has developed resistance to a wild-type RET inhibitor, or a patient with a particular RET mutant. The method includes the step of administering a compound or composition of the invention that is active against one or more RET resistant mutants. In certain embodiments, the RET resistant mutant is selected from V804L, V804M, V804E, Y806C, Y806S, Y806N, Y806H, G810R, G810S, L865V, L870F, S891A and M918T. By "active" is meant that a compound has an IC50 of less than 1 μΜ, 500 nM, 250 nM, 100 nM, 75 nM, 50 nM, 25 nM, 10 nM, or 5 nM when measured in a biochemical assay, against at least one resistant mutant.
The compounds may also be used to treat a subject having a RET-altered cell, cancer, gene, or gene product. The RET alteration may be, e.g. , a point mutation, insertion, deletion, amplification, or fusion, or a combination thereof.
The compounds may also be used to treat a subject having a RET-altered cell, cancer, gene, or gene product comprising a RET alteration described in Table 3 or Table 4 herein. In some embodiments, the subject has a fusion between RET and a RET fusion partner listed in Table 3, e.g. , comprises a fusion protein that comprises RET or a fragment thereof and a protein of Table 3 or fragment thereof. In some embodiments, the fusion partner is N-terminal or C- terminal of RET. In some embodiments, the subject has an alteration at a position in RET that is described in Table 4. In some embodiments, a subset of the subject's cells, e.g. , a subset of the subject' s tumor cells, comprise the RET alteration. In some embodiments, a subset of the subject' s cells, e.g. , a subset of the subject's tumor cells, are RET-altered. In some
embodiments, the subject has a cancer listed in Table 3, e.g. , the subject has both a RET mutation and a cancer listed in Table 3.
Table 3. RET fusions
Figure imgf000037_0001
Salivary Gland Cancer, Metastatic Colorectal Cancer; Lung
Adenocarcinoma, Adenosquamous Carcinomas; Diffuse Sclerosing Variant of Papillary Thyroid Cancer
TRIM33 NSCLC, Papillary Thyroid Cancer
ERC1 Papillary Thyroid Cancer, Breast Cancer
FGFRIOP CMML, Primary Myelofibrosis with secondary Acute Myeloid
Leukemia
MBD1 Papillary Thyroid Cancer
RAB61P2 Papillary Thyroid Cancer
PRKAR1A Papillary Thyroid Cancer
TRIM24 Papillary Thyroid Cancer
KTN1 Papillary Thyroid Cancer
GOLGA5 Papillary Thyroid Cancer, Spitzoid Neoplasms
HOOK3 Papillary Thyroid Cancer
KIAA1468 Papillary Thyroid Cancer, Lung Adenocarcinoma
TRIM27 Papillary Thyroid Cancer
AKAP13 Papillary Thyroid Cancer
FKBP15 Papillary Thyroid Cancer
SPECC1L Papillary Thyroid Cancer, Thyroid Gland Carcinoma
TBL1XR1 Papillary Thyroid Cancer, Thyroid Gland Carcinoma
CEP55 Diffuse Gastric Cancer
CUX1 Lung Adenocarcinoma
ACBD5 Papillary Thyroid Carcinoma
MYH13 Medullary Thyroid Carcinoma
PIBF1 Bronchiolus Lung Cell Carcinoma
KIAA1217 Papillary Thyroid Cancer, Lung Adenocarcinoma, NSCLC
MPRIP NSCLC
Table 4. RET mutations
Amino acid position 2 Amino acid position 665 (e.g. , H665Q) Amino acid position 666 (e.g. , K666E, K666M, or
Amino acid position 3
K666N)
Amino acid position 4 Amino acid position 686 (e.g. , S686N)
Amino acid position 5 Amino acid position 691 (e.g. , G691S)
Amino acid position 6 Amino acid position 694 (e.g. , R694Q)
Amino acid position 7 Amino acid position 700 (e.g. , M700L)
Amino acid position 8 Amino acid position 706 (e.g. , V706M or V706A)
Amino acid position 713 splice variant (e.g. ,
Amino acid position 11
E713K)
Amino acid position 12 Amino acid position 736 (e.g. , G736R)
Amino acid position 13 Amino acid position 748 (e.g. , G748C)
Amino acid position 20 Amino acid position 750 (e.g. , A750P)
Amino acid position 32 (e.g. , S32L) Amino acid position 765 (e.g. , S765P)
Amino acid position 34 (e.g. , D34S) Amino acid position 766 (e.g. , P766S or P766M6)
Amino acid position 40 (e.g. , L40P) Amino acid position 768 (e.g. , E768Q or E768D)
Amino acid position 64 (e.g. , P64L) Amino acid position 769 (e.g. , L769L)
Amino acid position 67 (e.g. , R67H) Amino acid position 770 (e.g. , R770Q)
Amino acid position 114 (e.g. , R114H) Amino acid position 771 (e.g. , D771N)
Amino acid position 136 (e.g. , glutamic
Amino acid position 777 (e.g. , N777S) acid to stop codon)
Amino acid position 145 (e.g. , V145G) Amino acid position 778 (e.g. , V778I)
Amino acid position 180 (e.g. , arginine to
Amino acid position 781 (e.g. , Q781R) stop codon)
Amino acid position 200 Amino acid position 790 (e.g. , L790F)
Amino acid position 292 (e.g. , V292M) Amino acid position 791 (e.g. , Y791F or Y791N)
Amino acid position 294 Amino acid position 802
Amino acid position 804 (e.g. , V804L, V804M,
Amino acid position 321 (e.g. , G321R)
V804M*, or V804E)
Amino acid position 330 (e.g. , R330Q) Amino acid position 805 (e.g. , E805K)
Amino acid position 806 (e.g. , E806C, Y806E,
Amino acid position 338 (e.g. , T338I)
Y806F, Y806S, Y806G, or Y806C)
Amino acid position 360 (e.g. , R360W) Amino acid position 818 (e.g. , E818K)
Amino acid position 373 (e.g. , alanine to
Amino acid position 819 (e.g. , S819I)
frameshift)
Amino acid position 393 (e.g. , F393L) Amino acid position 823 (e.g. , G823E)
Amino acid position 432 Amino acid position 826 (e.g. , Y826M)
Δ Amino acid residues 505-506 (6-Base
Pair In-Frame Germline Deletion in Exon Amino acid position 833 (e.g. , R833C)
7)
Amino acid position 510 (e.g. , A510V) Amino acid position 841 (e.g. , P841L or P841P) Amino acid position 511 (e.g. , E51 IK) Amino acid position 843 (e.g. , E843D)
Amino acid position 844 (e.g. , R844W, R844Q, or
Amino acid position 513 (e.g. , A513D)
R844L)
Amino acid position 515 (e.g. , C515S,
Amino acid position 848 (e.g. , M848T)
C515W)
Amino acid position 525 (e.g. , R525W) Amino acid position 852 (e.g. , 1852M)
Amino acid position 531 (e.g. , C531R, or
Amino acid position 866 (e.g. , A866W)
9 base pair duplication)
Amino acid position 532 (e.g. ,
Amino acid position 873 (e.g. , R873W) duplication)
Amino acid position 533 (e.g. , G533C or
Amino acid position 876 (e.g. , A876V)
G533S)
Amino acid position 550 (e.g. , G550E) Amino acid position 881 (e.g. , L881V)
Amino acid position 591 (e.g. , V591I) Amino acid position 882
Amino acid position 883 (e.g. , A883F, A883S,
Amino acid position 593 (e.g. , G593E)
A883T, or A883T*)
Amino acid position 600 (e.g. , R600Q) Amino acid position 884 (e.g. , E884K)
Amino acid position 602 (e.g. , I602V) Amino acid position 886 (e.g. , R886W)
Amino acid position 603 (e.g. , K603Q or
Amino acid position 891 (e.g. , S891A)
K603E2)
Amino acid position 606 (e.g. , Y606C) Amino acid position 897 (e.g. , R897Q)
Amino acid position 609 (e.g. , C609Y,
C609S, C609G, C609R, C609F, or Amino acid position 898 (e.g. , D898V)
C609W)
Amino acid position 611 (e.g. , C611R,
C611S, C611G, C611Y, C611F, or Amino acid position 901 (e.g. , E901K)
C611W)
Amino acid position 618 (e.g. , C618S,
C618Y, C618R, C618Y, C618G, C618F, Amino acid position 904 (e.g. , S904F or S904C2) C618W)
Amino acid position 619 (e.g. , F619F) Amino acid position 907 (e.g. , K907E or K907M)
Amino acid position 620 (e.g. , C620S,
C620W, C620R, C620G, C620L, C620Y, Amino acid position 908 (e.g. , R908K)
C620F)
Amino acid position 623 (e.g. , E623K) Amino acid position 911 (e.g. , G911D)
Amino acid position 624 (e.g. , D624N) Amino acid position 912 (e.g. , R912P, R912Q)
Amino acid position 630 (e.g. , C630A, Amino acid position 918 (e.g. , M918T, M918V, or C630R, C630S, C630Y, or C630F) M918L6)
Amino acid position 631 (e.g. , D631N,
D631Y, D631A, D631G, D631V, or Amino acid position 919 (e.g. , A919V)
D631E) Amino acid position 632 (e.g. , E632K or
Amino acid position 921 (e.g. , E921K)
E632G5)
Δ Amino acid residues 632-633 (6-Base
Pair In-Frame Germline Deletion in Exon Amino acid position 922 (e.g. , S922P or S922Y) 11)
Amino acid position 633 (e.g. , 9 base pair
Amino acid position 930 (e.g. , T930M) duplication)
Amino acid position 634 (e.g. , C634W,
C634Y, C634S, C634R, C634F, C634G,
Amino acid position 961 (e.g. , F961L)
C634L, C634A, or C634T, or an insertion
ELCR2, or a 12 base pair duplication)
Amino acid position 635 (e.g. , R635G) Amino acid position 972 (e.g. , R972G)
Amino acid position 636 (e.g. , T636P or
Amino acid position 982 (e.g. , R982C)
T636M4)
Amino acid position 640 (e.g. , A640G) Amino acid position 1009 (e.g. , M 1009V)
Amino acid position 641 (e.g. , A641S or
Amino acid position 1017 (e.g. , D1017N)
A641T8)
Amino acid position 648 (e.g. , V6481) Amino acid position 1041 (e.g. , V1041G)
Amino acid position 649 (e.g. , S649L) Amino acid position 1064 (e.g. , M1064T)
Amino acid position 664 (e.g. , A664D) RET+3
RET has two primary protein and mRNA isoforms, named RET51 and RET9. In embodiments, RET has a sequence of isoform RET51 as shown below as SEQ ID NO: 1. The kinase domain, corresponding to amino acids 724-1016 of SEQ ID NO: 1, is highlighted. Unless otherwise indicated, the amino acid positions described herein refer to the numbering of RET51 shown below.
SEQ ID NO: 1 :
10 20 30 40 50
MAKATSGAAG LRLLLLLLLP LLGKVALGLY FSRDAY EKL YVDQAAGTPL
60 70 80 90 100
LYVHALRDAP EEVPSFRLGQ HLYGTYRTRL HENNWICIQE DTGLLYLNRS
110 120 130 140 150
LDHSSWEKLS VRNRGFPLLT VYLKVFLSPT SLREGECQWP GCARVYFSFF
160 170 180 190 200
TSFPACSSL KPRELCFPET RPSFRIRE R PPGTFHQFRL LPVQFLCPNI
210 220 230 240 250 SVAYRLLEGE GLPFRCAPDS LEVSTRWALD REQREKYELV AVCTVHAGAR
260 270 280 290 300
EEW VPFPV TVYDEDDSAP TFPAGVDTAS AWEFKRKED TWATLRVFD
310 320 330 340 350
ADWPASGEL VRRYTSTLLP GDTWAQQTFR VEHWP ETSV QANGSFVRAT
360 370 380 390 400
VHDYRLVLNR MLS ISENRTM QLAVLVNDSD FQGPGAGVLL LHFNVSVLPV
410 420 430 440 450
SLHLPSTYSL SVSRRARRFA QIGKVCVENC QAFSGINVQY KLHSSGANGS
460 470 480 490 500
TLGWTSAED TSGILFVNDT KALRRPKCAE LHYMVVATDQ OTSRQAQAQL
510 520 530 540 550
LVTVEGSYVA EEAGCPLSCA VSKRRLECEE CGGLGSPTGR CEWRQGDGKG
560 570 580 590 600
ITRNFSTCSP STKTCPDGHC DWETQDINI CPQDCLRGSI VGGHEPGEPR
610 620 630 640 650
GIKAGYGTCN CFPEEEKCFC EPEDIQDPLC DELCRTVIAA AVLFSFIVSV
660 670 680 690 700
LLSAFCIHCY HKFAHKPP S SAE TFRRPA QAFPVSYSSS GARRPSLDSM
710 720 730 740 750
ENQVSVDAFK ILEDPKWEFP RKNLVLGKTL GEGEFGKWK ATAFHLKGRA
760 770 780 790 800
GYTTVAVK L KENASPSELR DLLSEFNVLK QVNHPHVIKL YGACSQDGPL
810 820 830 840 850
LLIVEYAKYG SLRGFLRESR KVGPGYLGSG GSRNSSSLDH PDERALTMGD
860 870 880 890 900
LISFAWQISQ G QYLAE KL VHP.DLAARN LVAEGRK K SDFGLSRDVY
910 920 930 940 950
EEDSYVKRSQ GRIPVK MAI ESLFDHIYTT QSDVWSFGVL LWEIVTLGGN
960 970 980 990 1000
PYPGIPPERL FNLLKTGHRM ERPDNCSEEM YRLMLQCWKQ EPDKRPVFAD
1010 1020 1030 1040 1050
ISKDLEKMMV KRRDYLDLAA STPSDSLIYD DGLSEEETPL VDCNNAPLPR
1060 1070 1080 1090 1100
ALPST IENK LYG SDPN P GESPVPLTRA DGTNTGFPRY PNDSVYANW
1110
LSPSAAKLMD TF S
In embodiments, RET has a sequence of isoform RET9 as shown below in SEQ ID NO: 2 (wherein the kinase domain is highlighted)
SEQ ID NO: 2:
10 20 30 40 50
MAKATSGAAG LRLLLLLLLP LLGKVALGLY FSRDAYWEKL YVDQAAGTPL
60 70 80 90 100
LYVHALRDAP EEVPSFRLGQ HLYGTYRTRL HENNWICIQE DTGLLYLNRS
110 120 130 140 150
LDHSSWEKLS VRNRGFPLLT VYLKVFLSPT SLREGECQWP GCARVYFSFF 160 170 180 190 200
NTSFPACSSL KPRELCFPET RPSFRIRENR PPGTFHQFRL LPVQFLCPNI
210 220 230 240 250
SVAYRLLEGE GLPF'RCAPDS LEVSTRWALD REQREKYELV AVCTVHAGAR
260 270 280 290 300
EEVVMVPFPV TVYDEDDSAP TFPAGVDTAS AVVEFKRKED TWATLRVFD
310 320 330 340 350
ADWPASGEL VRRYTSTLLP GDT AQQTFR VEH PNETSV QANGSFVRAT
360 370 380 390 400
VHDYRLVLNR NLSISENRT QLAVLVNDSD FQGPGAGVLL LHFNVSVLPV
410 420 430 440 450
SLHLPSTYSL SVSRRARRF QIGKVCVENC QAFSGINVQY KLHSSGANGS
460 470 480 490 500
TLGVVTSAED TSGILFVNDT KALRRPKCAE LHYMWATDQ QTSRQAQAQL
510 520 530 540 550
LVTVEGSYVA EEAGCPLSCA VSKRRLECEE CGGLGSPTGR CEWRQGDGKG
560 570 580 590 600
ITRNFSTCSP STKTCPDGHC DWETQDINI CPQDCLRGSI VGGHEPGEPR
610 620 630 640 650
GIKAGYGTCN CFPEEEKCFC EPEDIQDPLC DELCRTVIAA AVLFSFIVSV
660 670 680 690 700
LLSAFCIHCY H FAHKPPI S S EMTa'RRPA QAFPVSYSSS GARRPSLDSM
710 720 730 740 750
ENQVSVDAFK ILEDPKWEFP RKNLVLGKTL GEGEFGKVVK ATAFHLKGRA
760 770 780 790 800
GYTTVAVK L KENASPSELR DLLSEFNVLK QVNHPHVIKL YGACSQDGPL
810 820 830 840 850
LLIVEYAKYG SLRGFLRESR KVGPGYLGSG GSR SSSLDH PDERALTMGD
860 870 880 890 900
LISFA QISQ GMQYLAEMKL VHRDLAARNI LVAEGRKMKI SDFGLSRDVY
910 920 930 940 950
EEDSYVKRSQ GRIPVKWILAI ESLFDHIYTT QSDVWSFGVL LWEIVTLGGN
960 970 980 990 1000
PYPGIPPERL FNLLKTGHRM ERPDNCSEE YRLMLQC KQ EPDKRPVFAD
1010 1020 1030 1040 1050
ISKDLEKMMV KRRDYLDLAA STPSDSLIYD DGLSEEETPL VDCNNAPLPR
1060 1070
ALPSTWIENK LYGRI SHAFT RF
In embodiments, RET51 is encoded by a nucleic acid having the sequence of SEQ ID
NO: 3:
1 agtcccgcga ccgaagcagg gcgcgcagca gcgctgagtg ccccggaacg tgcgtcgcgc
61 ccccagtgtc cgtcgcgtcc gccgcgcccc gggcggggat ggggcggcca gactgagcgc
121 cgcacccgcc atccagaccc gccggcccta gccgcagtcc ctccagccgt ggccccagcg
181 cgcacgggcg atggcgaagg cgacgtccgg tgccgcgggg ctgcgtctgc tgttgctgct
241 gctgctgccg ctgctaggca aagtggcatt gggcctctac ttctcgaggg atgcttactg
301 ggagaagctg tatgtggacc aggcggccgg cacgcccttg ctgtacgtcc atgccctgcg
361 ggacgcccct gaggaggtgc ccagcttccg cctgggccag catctctacg gcacgtaccg
421 cacacggctg catgagaaca actggatctg catccaggag gacaccggcc tcctctacct 481 taaccggagc ctggaccata gctcctggga gaagctcagt gtccgcaacc gcggctttcc 541 cctgctcacc gtctacctca aggtcttcct gtcacccaca tcccttcgtg agggcgagtg 601 ccagtggcca ggctgtgccc gcgtatactt ctccttcttc aacacctcct ttccagcctg 661 cagctccctc aagccccggg agctctgctt cccagagaca aggccctcct tccgcattcg 721 ggagaaccga cccccaggca ccttccacca gttccgcctg ctgcctgtgc agttcttgtg 781 ccccaacatc agcgtggcct acaggctcct ggagggtgag ggtctgccct tccgctgcgc 841 cccggacagc ctggaggtga gcacgcgctg ggccctggac cgcgagcagc gggagaagta 901 cgagctggtg gccgtgtgca ccgtgcacgc cggcgcgcgc gaggaggtgg tgatggtgcc 961 cttcccggtg accgtgtacg acgaggacga ctcggcgccc accttccccg cgggcgtcga 1021 caccgccagc gccgtggtgg agttcaagcg gaaggaggac accgtggtgg ccacgctgcg 1081 tgtcttcgat gcagacgtgg tacctgcatc aggggagctg gtgaggcggt acacaagcac 1141 gctgctcccc ggggacacct gggcccagca gaccttccgg gtggaacact ggcccaacga 1201 gacctcggtc caggccaacg gcagcttcgt gcgggcgacc gtacatgact ataggctggt 1261 tctcaaccgg aacctctcca tctcggagaa ccgcaccatg cagctggcgg tgctggtcaa 1321 tgactcagac ttccagggcc caggagcggg cgtcctcttg ctccacttca acgtgtcggt 1381 gctgccggtc agcctgcacc tgcccagtac ctactccctc tccgtgagca ggagggctcg 1441 ccgatttgcc cagatcggga aagtctgtgt ggaaaactgc caggcattca gtggcatcaa 1501 cgtccagtac aagctgcatt cctctggtgc caactgcagc acgctagggg tggtcacctc 1561 agccgaggac acctcgggga tcctgtttgt gaatgacacc aaggccctgc ggcggcccaa 1621 gtgtgccgaa cttcactaca tggtggtggc caccgaccag cagacctcta ggcaggccca 1681 ggcccagctg cttgtaacag tggaggggtc atatgtggcc gaggaggcgg gctgccccct 1741 gtcctgtgca gtcagcaaga gacggctgga gtgtgaggag tgtggcggcc tgggctcccc 1801 aacaggcagg tgtgagtgga ggcaaggaga tggcaaaggg atcaccagga acttctccac 1861 ctgctctccc agcaccaaga cctgccccga cggccactgc gatgttgtgg agacccaaga 1921 catcaacatt tgccctcagg actgcctccg gggcagcatt gttgggggac acgagcctgg 1981 ggagccccgg gggattaaag ctggctatgg cacctgcaac tgcttccctg aggaggagaa 2041 gtgcttctgc gagcccgaag acatccagga tccactgtgc gacgagctgt gccgcacggt 2101 gatcgcagcc gctgtcctct tctccttcat cgtctcggtg ctgctgtctg ccttctgcat 2161 ccactgctac cacaagtttg cccacaagcc acccatctcc tcagctgaga tgaccttccg 2221 gaggcccgcc caggccttcc cggtcagcta ctcctcttcc ggtgcccgcc ggccctcgct 2281 ggactccatg gagaaccagg tctccgtgga tgccttcaag atcctggagg atccaaagtg 2341 ggaattccct cggaagaact tggttcttgg aaaaactcta ggagaaggcg aatttggaaa 2401 agtggtcaag gcaacggcct tccatctgaa aggcagagca gggtacacca cggtggccgt 2461 gaagatgctg aaagagaacg cctccccgag tgagcttcga gacctgctgt cagagttcaa 2521 cgtcctgaag caggtcaacc acccacatgt catcaaattg tatggggcct gcagccagga 2581 tggcccgctc ctcctcatcg tggagtacgc caaatacggc tccctgcggg gcttcctccg 2641 cgagagccgc aaagtggggc ctggctacct gggcagtgga ggcagccgca actccagctc 2701 cctggaccac ccggatgagc gggccctcac catgggcgac ctcatctcat ttgcctggca 2761 gatctcacag gggatgcagt atctggccga gatgaagctc gttcatcggg acttggcagc 2821 cagaaacatc ctggtagctg aggggcggaa gatgaagatt tcggatttcg gcttgtcccg 2881 agatgtttat gaagaggatt cctacgtgaa gaggagccag ggtcggattc cagttaaatg 2941 gatggcaatt gaatcccttt ttgatcatat ctacaccacg caaagtgatg tatggtcttt 3001 tggtgtcctg ctgtgggaga tcgtgaccct agggggaaac ccctatcctg ggattcctcc 3061 tgagcggctc ttcaaccttc tgaagaccgg ccaccggatg gagaggccag acaactgcag 3121 cgaggagatg taccgcctga tgctgcaatg ctggaagcag gagccggaca aaaggccggt 3181 gtttgcggac atcagcaaag acctggagaa gatgatggtt aagaggagag actacttgga 3241 ccttgcggcg tccactccat ctgactccct gatttatgac gacggcctct cagaggagga 3301 gacaccgctg gtggactgta ataatgcccc cctccctcga gccctccctt ccacatggat 3361 tgaaaacaaa ctctatggca tgtcagaccc gaactggcct ggagagagtc ctgtaccact 3421 cacgagagct gatggcacta acactgggtt tccaagatat ccaaatgata gtgtatatgc 3481 taactggatg ctttcaccct cagcggcaaa attaatggac acgtttgata gttaacattt 3541 ctttgtgaaa ggtaatggac tcacaagggg aagaaacatg ctgagaatgg aaagtctacc 3601 ggccctttct ttgtgaacgt cacattggcc gagccgtgtt cagttcccag gtggcagact 3661 cgtttttggt agtttgtttt aacttccaag gtggttttac ttctgatagc cggtgatttt 3721 ccctcctagc agacatgcca caccgggtaa gagctctgag tcttagtggt taagcattcc 3781 tttctcttca gtgcccagca gcacccagtg ttggtctgtg tccatcagtg accaccaaca 3841 ttctgtgttc acatgtgtgg gtccaacact tactacctgg tgtatgaaat tggacctgaa 3901 ctgttggatt tttctagttg ccgccaaaca aggcaaaaaa atttaaacat gaagcacaca 3961 cacaaaaaag gcagtaggaa aaatgctggc cctgatgacc tgtccttatt cagaatgaga 4021 gactgcgggg ggggcctggg ggtagtgtca atgcccctcc agggctggag gggaagaggg 4081 gccccgagga tgggcctggg ctcagcattc gagatcttga gaatgatttt tttttaatca 4141 tgcaaccttt ccttaggaag acatttggtt ttcatcatga ttaagatgat tcctagattt 4201 agcacaatgg agagattcca tgccatcttt actatgtgga tggtggtatc agggaagagg 4261 gctcacaaga cacatttgtc ccccgggccc accacatcat cctcacgtgt tcggtactga 4321 gcagccacta cccctgatga gaacagtatg aagaaagggg gctgttggag tcccagaatt 4381 gctgacagca gaggctttgc tgctgtgaat cccacctgcc accagcctgc agcacacccc 4441 acagccaagt agaggcgaaa gcagtggctc atcctacctg ttaggagcag gtagggcttg 4501 tactcacttt aatttgaatc ttatcaactt actcataaag ggacaggcta gctagctgtg 4561 ttagaagtag caatgacaat gaccaaggac tgctacacct ctgattacaa ttctgatgtg 4621 aaaaagatgg tgtttggctc ttatagagcc tgtgtgaaag gcccatggat cagctcttcc 4681 tgtgtttgta atttaatgct gctacaagat gtttctgttt cttagattct gaccatgact 4741 cataagcttc ttgtcattct tcattgcttg tttgtggtca cagatgcaca acactcctcc 4801 agtcttgtgg gggcagcttt tgggaagtct cagcagctct tctggctgtg ttgtcagcac 4861 tgtaacttcg cagaaaagag tcggattacc aaaacactgc ctgctcttca gacttaaagc 4921 actgatagga cttaaaatag tctcattcaa atactgtatt ttatataggc atttcacaaa 4981 aacagcaaaa ttgtggcatt ttgtgaggcc aaggcttgga tgcgtgtgta atagagcctt 5041 gtggtgtgtg cgcacacacc cagagggaga gtttgaaaaa tgcttattgg acacgtaacc 5101 tggctctaat ttgggctgtt tttcagatac actgtgataa gttcttttac aaatatctat 5161 agacatggta aacttttggt tttcagatat gcttaatgat agtcttacta aatgcagaaa 5221 taagaataaa ctttctcaaa ttattaaaaa tgcctacaca gtaagtgtga attgctgcaa 5281 caggtttgtt ctcaggaggg taagaactcc aggtctaaac agctgaccca gtgatgggga 5341 atttatcctt gaccaattta tccttgacca ataacctaat tgtctattcc tgagttataa 5401 aagtccccat ccttattagc tctactggaa ttttcataca cgtaaatgca gaagttacta 5461 agtattaagt attactgagt attaagtagt aatctgtcag ttattaaaat ttgtaaaatc 5521 tatttatgaa aggtcattaa accagatcat gttccttttt ttgtaatcaa ggtgactaag 5581 aaaatcagtt gtgtaaataa aatcatgtat cataaaaaaa aaaaaaaaa
//
In embodiments, RET9 is encoded by a nucleic acid having the sequence of SEQ ID NO:
1 agtcccgcga ccgaagcagg gcgcgcagca gcgctgagtg ccccggaacg tgcgtcgcgc 61 ccccagtgtc cgtcgcgtcc gccgcgcccc gggcggggat ggggcggcca gactgagcgc 121 cgcacccgcc atccagaccc gccggcccta gccgcagtcc ctccagccgt ggccccagcg 181 cgcacgggcg atggcgaagg cgacgtccgg tgccgcgggg ctgcgtctgc tgttgctgct 241 gctgctgccg ctgctaggca aagtggcatt gggcctctac ttctcgaggg atgcttactg 301 ggagaagctg tatgtggacc aggcggccgg cacgcccttg ctgtacgtcc atgccctgcg 361 ggacgcccct gaggaggtgc ccagcttccg cctgggccag catctctacg gcacgtaccg 421 cacacggctg catgagaaca actggatctg catccaggag gacaccggcc tcctctacct 481 taaccggagc ctggaccata gctcctggga gaagctcagt gtccgcaacc gcggctttcc 541 cctgctcacc gtctacctca aggtcttcct gtcacccaca tcccttcgtg agggcgagtg 601 ccagtggcca ggctgtgccc gcgtatactt ctccttcttc aacacctcct ttccagcctg 661 cagctccctc aagccccggg agctctgctt cccagagaca aggccctcct tccgcattcg 721 ggagaaccga cccccaggca ccttccacca gttccgcctg ctgcctgtgc agttcttgtg 781 ccccaacatc agcgtggcct acaggctcct ggagggtgag ggtctgccct tccgctgcgc 841 cccggacagc ctggaggtga gcacgcgctg ggccctggac cgcgagcagc gggagaagta 901 cgagctggtg gccgtgtgca ccgtgcacgc cggcgcgcgc gaggaggtgg tgatggtgcc 961 cttcccggtg accgtgtacg acgaggacga ctcggcgccc accttccccg cgggcgtcga 1021 caccgccagc gccgtggtgg agttcaagcg gaaggaggac accgtggtgg ccacgctgcg 1081 tgtcttcgat gcagacgtgg tacctgcatc aggggagctg gtgaggcggt acacaagcac 1141 gctgctcccc ggggacacct gggcccagca gaccttccgg gtggaacact ggcccaacga 1201 gacctcggtc caggccaacg gcagcttcgt gcgggcgacc gtacatgact ataggctggt 1261 tctcaaccgg aacctctcca tctcggagaa ccgcaccatg cagctggcgg tgctggtcaa 1321 tgactcagac ttccagggcc caggagcggg cgtcctcttg ctccacttca acgtgtcggt 1381 gctgccggtc agcctgcacc tgcccagtac ctactccctc tccgtgagca ggagggctcg 1441 ccgatttgcc cagatcggga aagtctgtgt ggaaaactgc caggcattca gtggcatcaa 1501 cgtccagtac aagctgcatt cctctggtgc caactgcagc acgctagggg tggtcacctc 1561 agccgaggac acctcgggga tcctgtttgt gaatgacacc aaggccctgc ggcggcccaa 1621 gtgtgccgaa cttcactaca tggtggtggc caccgaccag cagacctcta ggcaggccca 1681 ggcccagctg cttgtaacag tggaggggtc atatgtggcc gaggaggcgg gctgccccct 1741 gtcctgtgca gtcagcaaga gacggctgga gtgtgaggag tgtggcggcc tgggctcccc 1801 aacaggcagg tgtgagtgga ggcaaggaga tggcaaaggg atcaccagga acttctccac 1861 ctgctctccc agcaccaaga cctgccccga cggccactgc gatgttgtgg agacccaaga 1921 catcaacatt tgccctcagg actgcctccg gggcagcatt gttgggggac acgagcctgg 1981 ggagccccgg gggattaaag ctggctatgg cacctgcaac tgcttccctg aggaggagaa 2041 gtgcttctgc gagcccgaag acatccagga tccactgtgc gacgagctgt gccgcacggt 2101 gatcgcagcc gctgtcctct tctccttcat cgtctcggtg ctgctgtctg ccttctgcat 2161 ccactgctac cacaagtttg cccacaagcc acccatctcc tcagctgaga tgaccttccg 2221 gaggcccgcc caggccttcc cggtcagcta ctcctcttcc ggtgcccgcc ggccctcgct 2281 ggactccatg gagaaccagg tctccgtgga tgccttcaag atcctggagg atccaaagtg 2341 ggaattccct cggaagaact tggttcttgg aaaaactcta ggagaaggcg aatttggaaa 2401 agtggtcaag gcaacggcct tccatctgaa aggcagagca gggtacacca cggtggccgt 2461 gaagatgctg aaagagaacg cctccccgag tgagcttcga gacctgctgt cagagttcaa 2521 cgtcctgaag caggtcaacc acccacatgt catcaaattg tatggggcct gcagccagga 2581 tggcccgctc ctcctcatcg tggagtacgc caaatacggc tccctgcggg gcttcctccg 2641 cgagagccgc aaagtggggc ctggctacct gggcagtgga ggcagccgca actccagctc 2701 cctggaccac ccggatgagc gggccctcac catgggcgac ctcatctcat ttgcctggca 2761 gatctcacag gggatgcagt atctggccga gatgaagctc gttcatcggg acttggcagc 2821 cagaaacatc ctggtagctg aggggcggaa gatgaagatt tcggatttcg gcttgtcccg 2881 agatgtttat gaagaggatt cctacgtgaa gaggagccag ggtcggattc cagttaaatg 2941 gatggcaatt gaatcccttt ttgatcatat ctacaccacg caaagtgatg tatggtcttt 3001 tggtgtcctg ctgtgggaga tcgtgaccct agggggaaac ccctatcctg ggattcctcc 3061 tgagcggctc ttcaaccttc tgaagaccgg ccaccggatg gagaggccag acaactgcag 3121 cgaggagatg taccgcctga tgctgcaatg ctggaagcag gagccggaca aaaggccggt 3181 gtttgcggac atcagcaaag acctggagaa gatgatggtt aagaggagag actacttgga 3241 ccttgcggcg tccactccat ctgactccct gatttatgac gacggcctct cagaggagga 3301 gacaccgctg gtggactgta ataatgcccc cctccctcga gccctccctt ccacatggat 3361 tgaaaacaaa ctctatggta gaatttccca tgcatttact agattctagc accgctgtcc 3421 cctctgcact atccttcctc tctgtgatgc tttttaaaaa tgtttctggt ctgaacaaaa 3481 ccaaagtctg ctctgaacct ttttatttgt aaatgtctga ctttgcatcc agtttacatt 3541 taggcattat tgcaactatg tttttctaaa aggaagtgaa aataagtgta attaccacat 3601 tgcccagcaa cttaggatgg tagaggaaaa aacagatcag ggcggaactc tcaggggaga 3661 ccaagaacag gttgaataag gcgcttctgg ggtgggaatc aagtcatagt acttctactt 3721 taactaagtg gataaatata caaatctggg gaggtattca gttgagaaag gagccaccag 3781 caccactcag cctgcactgg gagcacagcc aggttccccc agacccctcc tgggcaggca 3841 ggtgcctctc agaggccacc cggcactggc gagcagccac tggccaagcc tcagccccag 3901 tcccagccac atgtcctcca tcaggggtag cgaggttgca ggagctggct ggccctggga 3961 ggacgcaccc ccactgctgt tttcacatcc tttcccttac ccaccttcag gacggttgtc 4021 acttatgaag tcagtgctaa agctggagca gttgcttttt gaaagaacat ggtctgtggt 4081 gctgtggtct tacaatggac agtaaatatg gttcttgcca aaactccttc ttttgtcttt 4141 gattaaatac tagaaattta aaaaaaaaaa aaaa
// The compounds and compositions described herein can be administered alone or in combination with other compounds, including other RET-modulating compounds, or other therapeutic agents. In some embodiments, the compound or composition of the invention may be administered in combination with one or more compounds selected from Cabozantinib (COMETRIQ), Vandetanib (CALPRESA), Sorafenib (NEXAVAR), Sunitinib (SUTENT), Regorafenib (STAVARGA), Ponatinib (ICLUSIG), Bevacizumab (AVASTIN), Crizotinib (XALKORI), or Gefitinib (IRESSA). The compound or composition of the invention may be administered simultaneously or sequentially with the other therapeutic agent by the same of different routes of administration. The compound of the invention may be included in a single formulation with the other therapeutic agent or in separate formulations.
EXAMPLES
The following examples are intended to be illustrative, and are not meant in any way to be limiting.
Synthesis
Compounds of the invention, including salts and N -oxides thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes, such as those in the Schemes below. The reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g. , temperatures which can range from the solvent' s freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.
Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Wuts and Greene, Protective Groups in Organic Synthesis, 4th ed., John Wiley & Sons: New Jersey, (2006), which is incorporated herein by reference in its entirety.
Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic
1 13
resonance (NMR) spectroscopy (e.g. , H or C), infrared (IR) spectroscopy, spectrophotometry (e.g. , UV- visible), mass spectrometry (MS), or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC). Analytical instruments and methods for compound characterization:
LC-MS: Unless otherwise indicated, all liquid chromatography-mass spectrometry (LC- MS) data (sample analyzed for purity and identity) were obtained with an Agilent model- 1260 LC system using an Agilent model 6120 mass spectrometer utilizing ES-API ionization fitted with an Agilent Poroshel 120 (EC-C 18, 2.7um particle size, 3.0 x 50mm dimensions) reverse- phase column at 22.4 degrees Celsius. The mobile phase consisted of a mixture of solvent 0.1% formic acid in water and 0.1% formic acid in acetonitrile. A constant gradient from 95% aqueous/5% organic to 5% aqueous/95% organic mobile phase over the course of 4 minutes was utilized. The flow rate was constant at lmL/min.
Prep LC-MS: Preparative HPLC was performed on a Shimadzu Discovery VP®
Preparative system fitted with a Luna 5u C18(2) 100A, AXIA packed, 250 x 21.2 mm reverse- phase column at 22.4 degrees Celsius. The mobile phase consisted of a mixture of solvent 0.1% formic acid in water and 0.1% formic acid in acetonitrile. A constant gradient from 95% aqueous/5% organic to 5% aqueous/95% organic mobile phase over the course of 25 minutes was utilized. The flow rate was constant at 20 niL/min. Reactions carried out in a microwave were done so in a Biotage Initiator microwave unit.
Silica gel chromatography: Silica gel chromatography was performed on either a
Teledyne Isco CombiFlash® Rf unit or a Biotage® Isolera Four unit.
Proton NMR: Unless otherwise indicated, all 1H NMR spectra were obtained with a Varian 400MHz Unity Inova 400 MHz NMR instrument (acquisition time = 3.5 seconds with a 1 second delay; 16 to 64 scans). Where characterized, all protons were reported in OMSO-d6 solvent as parts-per million (ppm) with respect to residual DMSO (2.50 ppm). The below Schemes are meant to provide general guidance in connection with preparing the compounds of the invention. One skilled in the art would understand that the preparations shown in the Schemes can be modified or optimized using general knowledge of organic chemistry to prepare various compounds of the invention.
Synthetic Protocol 1:
Figure imgf000049_0001
An aryl dihalide can be treated with an organolithium or organomagnesium halide reagent, such as n-BuLi or z'-PrMgCl, and the arylmetal reagent can then undergo addition to an ester substituted cyclobutanone (either commercially available or prepared as described in "Synthesis of Ketone Intermediates" in Example 6). The remaining halide can then undergo a coupling reaction with an arylamine under SnAr conditions or metal-catalyzed coupling conditions to give a tricyclic ester intermediate. The ester can then be hydrolyzed under basic conditions to give an acid, which can then undergo an amide coupling reaction with an amine (either commercially available or prepared as described in "Synthesis of Amine Intermediates" in Example 8). The amides are examples of RET inhibitors described herein, but can also be further modified. For example, the tertiary alcohol can be treated with a fluorinating reagent such as DAST to give a mixture of deoxyfluorinated products which are also examples of RET inhibitors. Synthetic Protocol 2
Hydrolysis
Figure imgf000050_0001
PdCI2dppf
Figure imgf000050_0002
A substituted cycloalkyl iodide (either commercially available or prepared as described in "Synthesis of Iodide Intermediates") is treated with activated zinc. The zinc could be activated by a variety methods, including but not limited to the method of Reike or treatment with TMS-Cl and 1,2-dibromoethane. The cycloalkyl zinc reagent can then be coupled to a heteroaryl dihalide with palladium catalysis under Negishi coupling conditions. The resulting carbon-carbon can form to give a mixture of diastereomers, which can be separated by chromatography or other separation techniques at this stage. Alternatively the diastereomers can be used as a mixture in the subsequent transformations and separated at a different stage. The remaining heteroaryl halide can then undergo displacement with an aryl amine under either SnAr conditions or palladium mediated coupling conditions. The tricyclic carboxylic ester can then be hydrolyzed under acidic or basic conditions to provide a carboxylic acid intermediate. The carboxylic acid intermediate can then be coupled to a variety of amines, such as those described below under the heading "Synthesis of Amine Intermediates" in Example 8, to provide the amide final product. Synthetic Protocol 3:
Figure imgf000051_0001
A heteroaryl dihalide can be coupled to an amino pyrazole under nucleophilic aromatic substitution reaction conditions using a base such as diisopropylethylamine (DIPEA) or triethylamine (TEA) in a polar solvent to provide the bicyclic ring system. The bicyclic heteroaryl halide can then be coupled to an excess of alkyl zinc reagent (typically 2
equivalents)(M = Zn) via a palladium-mediated coupling reaction, e.g. Negishi coupling, to provide the tricyclic ring system. The alkylzinc reagents are prepared from zinc insertion into the carbon-halide bond of an ester-substituted alkyl halide, which are either commercially available or prepared as described in "Synthesis of Iodide Intermediates". The coupling reaction can give a mixture of diastereoisomers, which in some instances can be separated directly and in other instances are separated at a further stage. The carboxylic ester can then be hydrolyzed under acidic or basic conditions to provide a carboxylic acid intermediate. The carboxylic acid intermediate can then be coupled to a variety of amines, such as those described below under the heading "Synthesis of Amine Intermediates," in Example 8 to provide the amide final product. Example 1. General Synthesis of Compound 109 and Related Analogs
Step 1: Synthesis of methyl 3-(6-bromo-4-methylpyridin-2-yl)-3- hydroxycyclobutanecarboxylate
Figure imgf000052_0001
A solution of 2,6-dibromo-4-methylpyridine (1.50 g, 5.97 mmol) in DCM (30 mL) was cooled to -78 °C, and n-BuLi (2.5 M, 2.60 mL, 6.56 mmol) was added dropwise to the above solution at -78 °C. The solution was stirred at -78 °C for another 15 min. Methyl 3- oxocyclobutanecarboxylate (917 mg, 7.16 mmol) was added to the solution, and the resultant mixture was stirred at -78 °C for 30 min. The mixture was then quenched by addition of saturated aqueous NH4C1 solution and extracted with DCM. Organic layers were combined, dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column (PE:EA = 2: 1) to give methyl 3-(6-bromo-4-methylpyridin-2-yl)-3-hydroxycyclobutanecarboxylate (1.0 g, 56%) as a white solid, MS (ES+) Ci2Hi4BrN03 requires: 299, found: 300 [M+H]+.
Step 2: Synthesis of 3-hydroxy-3-(4-methyl-6-(5-methyl-lH-pyrazol-3-ylamino)pyridin-2- yl)cyclobutanecarboxylate
Figure imgf000052_0002
A mixture of methyl 3-(6-bromo-4-methylpyridin-2-yl)-3- hydroxycyclobutanecarboxylate (400 mg, 1.33 mmol), 5-methyl-lH-pyrazol-3-amine (258 mg, 2.66 mmol), t-BuXPhos (69 mg, 0.40 mmol), Pd2(dba)3 (182 mg, 0.20 mmol) and KOAc (391mg, 3.99 mmol) in DMA (6 mL) was heated to 140 °C for 1 h under microwave irradiation. After cooling to ambient temperature, the mixture was concentrated and purified by silica gel column (PE:EA = 1:2) to give 3-hydroxy-3-(4-methyl-6-(5-methyl-lH-pyrazol-3- ylamino)pyridin-2-yl)cyclobutanecarboxylate (120 mg, 29%) as a white solid. MS (ES+) Ci6H2oN403 requires: 316, found: 317 [M+H]+.
Step 3: Synthesis of 3-hydroxy-3-(4-methyl-6-(5-methyl-lH-pyrazol-3-ylamino)pyridin-2- yl)cyclobutanecarboxylate
Figure imgf000053_0001
To a solution of 3-hydroxy-3-(4-methyl-6-(5-methyl- lH-pyrazol-3-ylamino)pyridin-2- yl)cyclobutanecarboxylate (120 mg, 0.38 mmol) in MeOH (5 mL) was added 2 M aqueous LiOH (0.5 mL, 1 mmol) at 25 °C. The solution was stirred at 25 °C for 15 h. The solution was concentrated to remove MeOH. The water solution was acidified by 2 M HCl to bring pH to 6. The precipitated solid was collected and dried to give 3-hydroxy-3-(4-methyl-6-(5-methyl-lH- pyrazol-3-ylamino)pyridin-2-yl)cyclobutanecarboxylate (100 mg, 88%) as a yellow solid. MS (ES+) Ci5Hi8N403 requires: 302, found: 303 [M+H]+.
Step 4: Synthesis of (lS,4R)-N-((S)-l-(6-(4-fluoro-lH-pyrazol-l-yl)pyridin-3-yl)ethyl)-4- hydroxy-4-(4-methyl-6-(5-methyl-lH-pyrazol-3-ylamino)pyridin-2- yl)cyclohexanecarboxamide Compound 109)
Figure imgf000053_0002
A mixture of 3-hydroxy-3-(4-methyl-6-(5-methyl- lH-pyrazol-3-ylamino)pyridin-2- yl)cyclobutanecarboxylate (100 mg, 0.33 mmol), (S)-l-(6-(4-fluoro-lH-pyrazol-l-yl)pyridin-3- yl)ethanamine hydrochloride (80 mg, 0.33 mmol), HATU (125 mg, 0.33 mmol) and DIEA (128 mg, 0.99 mmol) in DMA (3 mL) was stirred 25 °C for 2 h. The solution was concentrated and purified by preparative HPLC to give the title product (60 mg, 37%) as a white solid. MS (ES+) C25H27FN8O2 requires: 490, found: 491 [M + H]+. 1H-NMR (400 MHz, OMSO-d6) δ ppm 11.70 (s, 1H), 8.86 (s, 1H), 8.68 (d, 1H, J = 4.8 Hz), 8.39 (d, 1H, J = 0.8 Hz), 8.35 (d, 1H, J = 8.0 Hz), 7.95-7.86 (m, 3H), 6.94 (s, 1H), 6.74 (s, 1H), 6.14 (s, 1H), 5.68 (s, 1H), 5.03-5.00 (m, 1H), 3.00- 2.98 (m, 1H), 2.63-2.55 (m, 2H), 2.42-2.32 (m, 2H), 2.21 (s, 3H), 2.18 (s, 3H), 1.39 (d, 3H, J = 7.2 Hz).
Example 2. General Synthesis of Compound 113 and Related Analogs
Step 1: Synthesis of (lS,3R)-3-fluoro-N-((S)-l-(6-(4-fluoro-lH-pyrazol-l-yl)pyridin-3- yl)ethyl)-3-(4-methyl-6-(5-methyl-lH-pyrazol-3-ylamino)pyridin-2- yl)cyclobutanecarboxamide
Figure imgf000054_0001
A mixture of (lS,3R)-N-((S)- l-(6-(4-fluoro- lH-pyrazol-l-yl)pyridin-3-yl)ethyl)-3- hydroxy-3-(4-methyl-6-((5-methyl-lH-pyrazol-3-yl)amino)pyridin-2- yl)cyclobutanecarboxamide (40 mg, 0.082 mmol) in DCM (4 mL) was cooled to 0°C. DAST (39 mg, 0.24 mmol) was added to the mixture at 0°C. The resultant mixture was stirred at 25 °C for 1 h. The mixture was concentrated and purified by Prep-HPLC to give the title compound (15.6 mg, 39%) as a white solid. MS (ES+) C25H26F2N8O requires: 492, found: 493 [M+H]+. 1H-NMR (400 MHz, DMSO-d6) δ ppm 12.50- 11.50 (br, 1H), 10.00-9.00 (br, 1H), 8.66 (d, 1H, J = 4.0 Hz), 8.56 (d, 1H, J = 6.0 Hz), 8.39 (d, 1H, J = 2.0 Hz), 7.94-7.85 (m, 3H), 6.82 (s, 1H), 6.69 (s, 1H), 6.34 (s, 1H), 5.09-5.05 (m, 1H), 3.46-3.40 (m, 2H), 3.29-2.95 (m, 2H), 2.55-2.50 (m, 1H), 2.24
(s, 3H), 2.16 (s, 3H), 1.42 (d, 3H, J = 7.2 Hz).
Example 3. Synthesis of Compound 117 and Related Analogs
Step 1: Synthesis of methyl 3-(6-bromo-4-methylpyridin-2-yl)-3-methoxycyclobutane-l- carboxylate
Figure imgf000055_0001
A mixture of methyl 3-(6-bromo-4-methylpyridin-2-yl)-3- hydroxycyclobutanecarboxylate (2.2 g, 7.3 mmol) in DMF (66 mL) was cooled to 0 °C. Sodium hydride (60% dispersion in oil, 1.45 g, 36.6 mmol) min was added, and after 15 min
iodomethane (2.08 g, 14.7 mmol) was added. The cooling bath was removed and the reaction mixture was stirred for 3 h at ambient temperature. The mixture was then partitioned between ethyl acetate and water, and the organic layer was washed with brine. The washed organic layer was dried over sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography on silica gel (gradient elution, 0 to 100% ethyl acetate- hexanes) to give methyl 3-(6-bromo-4-methylpyridin-2-yl)-3-methoxycyclobutane-l-carboxylate (1.6 g, 70%).
Steps 2-4: Synthesis of (lS,3R)-N-((S)-l-(6-(4-fluoro-lH-pyrazol-l-yl)pyridin-3-yl)ethyl)-3- methoxy-3-(4-methyl-6-((5-methyl-lH-pyrazol-3-yl)amino)pyridin-2-yl)cyclobutane-l- carboxamide
Figure imgf000056_0001
The title compound was prepared from methyl 3-(6-bromo-4-methylpyridin-2-yl)-3- methoxycyclobutane-l-carboxylate using the procedures described in Synthetic Protocol land Example 1. MS (ES+) C26H29FN802 requires: 504, found: 505 [M + H]+. 1H-NMR (400 MHz, DMSO-d6) δ 8.68 (d, J = 4.5 Hz, 1H), 8.51 (d, J = 7.7 Hz, 1H), 8.40 (d, / = 1.7 Hz, 1H), 7.95 - 7.88 (m, 3H), 7.25 (s, 1H), 7.07 (s, 1H), 5.98 (s, 1H), 5.03 - 4.98 (m, 1H), 3.07 (s, 3H), 2.97 - 2.83 (m, 2H), 2.58 (t, J = 9.2 Hz, 3H), 2.49 (s, 3H), 2.27 (s, 3H), 1.41 (d, J = 7.0 Hz, 3H).
Example 4. General Synthesis of Compound 122 and Related Analogs
Step 1: Synthesis of ethyl (ls,3s)-3-(2-chloro-6-methylpyrimidin-4-yl)-l- methoxycyclobutane-l-carbox late
Figure imgf000056_0002
Ethyl 3-iodo-l-methoxycyclobutane-l-carboxylate (1.00 g, 3.52 mmol) was dissolved in dimethylacetamide (11.7 mL) in a pressure vessel under a stream of nitrogen. Rieke Zinc (5.1 mL of a 50 mg/mL suspension in THF, 3.87 mmol) was added quickly via syringe. The vessel was capped and stirred at ambient temperature for 15 minutes. The vessel was opened under a stream of nitrogen and 2,4-dichloro-6-methylpyrimidine (689 mg, 4.22 mmol) was added followed by PdCl2dppf (258 mg, 0.352 mmol). The vessel was capped and heated to 70 °C for 3 h. LCMS of the crude reaction mixture showed a -3: 1 ratio of product isomers. The reaction mixture was then cooled to room temperature, diluted with ethyl acetate, and filtered through celite. The filtrate was transferred to a separatory funnel and washed with water (3x), brine, and dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography on silica gel (gradient elution, 0 to 50% ethyl acetate -hexanes) to give ethyl (lS,3S)-3-(2-chloro-6-methylpyrimidin-4-yl)-l- methoxycyclobutane-l-carboxylate (323 mg, 32%) as a colorless oil. The minor isomer was discarded. MS (ES+) C15H22N2O3S requires: 310, found: 311 [M+H]+.
Steps 2-4: Synthesis of (lR,3S)-N-((S)-l-(6-(4-fluoro-lH-pyrazol-l-yl)pyridin-3-yl)ethyl)-3- (6-methyl-2-((5-methyl-lH-pyrazol-3-yl)amino)pyrimidin-4-yl)cyclobutane-l-carboxamide
Figure imgf000057_0001
The title compound was prepared from ethyl (lS,3S)-3-(2-chloro-6-methylpyrimidin-4- yl)-l-methoxycyclobutane-l-carboxylate (192 mg, 0.53 mmol) using the same three-step procedure (cross-coupling, hydrolysis, and amide coupling) as in Synthetic Protocol land Example 1 to give a white solid. MS (ES+) C25H28FN9O2 requires: 505, found: 506 [M + H]+. 1H-NMR (400 MHz, DMSO- 6) δ 11.77 (s, 1H), 9.24 (s, 1H), 8.67 (dd, J = 4.5, 0.8 Hz, 1H), 8.52 (d, = 8.2 Hz, 1H), 8.44 (d, = 2.2 Hz, 1H), 7.99 (dd, = 8.6, 2.3 Hz, 1H), 7.94 - 7.74 (m, 2H), 6.54 (s, 2H), 5.17 - 5.01 (m, 1H), 3.16 - 3.03 (m, 4H), 2.71 - 2.60 (m, 1H), 2.57 - 2.36 (m, 4H), 2.26 (s, 3H), 2.17 (s, 3H), 1.47 (d, 7 = 7.1 Hz, 3H).
Example 5. General Synthesis of Compound 108 and Related Analogs
Step 1: Synthesis of 2-chloro-6-methyl-N-(5-methyl-lH-pyrazol-3-yl)pyrimidin-4-amine
Figure imgf000058_0001
A suspension of 2,4-dichloro-6-methyl-pyrimidine (120.00 g, 736.2 mmol, 1.00 eq) , 5- methyl-lH-pyrazol-3-amine (78.65 g, 0.81 mol, 1.10 eq) and DIPEA (142.72 g, 1.10 mol, 1.50 eq) in DMSO (400 mL) was heated at 60 °C for 16 hrs. TLC (PE/EA, 5: 1, 1: 1) showed the reaction was complete. The reaction mixture was cooled to 30 °C and poured into ice-water (800 mL). The resulting mixture was extracted with MTBE (800 mL x 10). The combined organic layers were washed with water (400 mL x 3), brine (400 mL x 3) and dried over Na2S04. After filtration, the filtrate was concentrated under reduced pressure and the residue was recrystallized from DCM ( 10 mL/g) to afford 2-chloro-6-methyl-N-(5-methyl-lH-pyrazol-3-yl)pyrimidin-4- amine (105.60 g, 472.14 mmol, 64%) as a yellow solid. The structure was confirmed by LC-MS and NMR.
Step 2: Synthesis of methyl l-methyl-3-(4-methyl-6-((5-methyl-lH-pyrazol-3- yl)amino)pyrimidin-2-yl)cyclobutane-l-carboxylate
Figure imgf000058_0002
PdCI2dppf
Methyl 3-iodo-l-methylcyclobutane-l-carboxylate (659 mg, 2.59 mmol) was dissolved in dimethylacetamide (3.2 mL) in a microwave reaction vial. The vial was evacuated and backfilled with nitrogen. Rieke Zinc (4.2 mL of a 50 mg/mL suspension in THF, 3.2 mmol) was added quickly via syringe. The vessel was capped and stirred at ambient temperature for 15 minutes. The vessel was opened under a stream of nitrogen and 2-chloro-6-methyl-N-(5-methyl- lH-pyrazol-3-yl)pyrimidin-4-amine (290 mg, 1.30 mmol) was added followed by PdCl2dppf (285 mg, 0.389 mmol). The vessel was capped and heated to 80 °C for 2 h. The reaction mixture was then cooled to room temperature, diluted with ethyl acetate, and filtered through celite. The filtrate was transferred to a separatory funnel and washed with water (3x), brine, and dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography on silica gel (gradient elution, 0 to 10% methanol-ethyl acetate) to give methyl l-methyl-3-(4-methyl-6-((5-methyl-lH-pyrazol-3- yl)amino)pyrimidin-2-yl)cyclobutane-l-carboxylate (80 mg, 20%) as a light brown solid. The mixture of diastereomers was not separated at this point. MS (ES+) C16H21N5O2 requires: 315, found: 316 [M+H]+.
Steps 3 and 4: Synthesis of (lR,3S)-N-((S)-l-(6-(4-fluoro-lH-pyrazol-l-yl)pyridin-3- yl)ethyl)-l-methyl-3-(4-methyl-6-((5-methyl-lH-pyrazol-3-yl)amino)pyrimidin-2- yl)cyclobutane-l-carboxamide (Compound 108) and (lS,3R)-N-((S)-l-(6-(4-fluoro-lH- pyrazol-l-yl)pyridin-3-yl)ethyl)-l-methyl-3-(4-methyl-6-((5-methyl-lH-pyrazol-3- yl)amino rimidin-2-yl)cyclobutane-l-carboxamide (Compound 107)
Figure imgf000059_0001
The title compounds were prepared from methyl l-methyl-3-(4-methyl-6-((5-methyl-lH- pyrazol-3-yl)amino)pyrimidin-2-yl)cyclobutane-l-carboxylate (82 mg, 0.26 mmol) using the same two-step procedure (hydrolysis and amide coupling) as in Synthetic Protocol 1. The diastereomers were separated by reverse-phase HPLC (gradient elution, 10% to 50% acetonitrile- water with 0.1% TFA additive). The fractions containing the compounds were combined and partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution. The organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated. Peak 1 was Compound 107 (white solid, 5 mg, 4% over two steps). Peak 2 was Compound 108 (white solid, 23 mg, 18% over two steps). The spectral data for these two compounds is presented in the compound table. Example 6. Synthesis of Ketone Intermediates
Ethyl l-methoxy-3-oxocvclobutane-l-carboxylate
Figure imgf000060_0001
Figure imgf000060_0002
Step 1: Synthesis of 3-(benzyloxy)-l-methoxycyclobutane-l-carboxylic acid
A solution of KOH (12.74 g, 227.0 mmol) in MeOH (70 mL) was added to mixture of 3- (benzyloxy)cyclobutan-l-one (5.00 g, 28.4 mmol) and bromoform (57.4 g, 227 mmol) was added at 0°C. The cooling bath was removed and the mixture was stirred at 20 °C for 16 h. LCMS showed reaction was completed and major was desired product. Water (100 mL) was then added and the mixture was and extracted with DCM (3 x 80 mL). The aqueous phase was adjusted pH to 3 with aqueous hydrochloric acid solution (0.5 N), then extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (3 x 50 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. Crude product (4.8 g) was obtained as brown solid which was used to next step directly without further purification
Step 2: Synthesis of ethyl 3-(benzyloxy)-l-methoxycyclobutane-l-carboxylate
Potassium carbonate (5.62 g, 40.6 mmol) and iodoethane (4.75 g, 30.5 mmol) were added to a solution of 3-(benzyloxy)-l-methoxycyclobutane-l-carboxylic acid (4.80 g, 20.3 mmol) in DMF (40 mL) at 0°C. The reaction mixture was stirred at 20 °C for 16 h, then was partitioned between water and ethyl acetate. The aqueous layer was further extracted with ethyl acetate (2 x), and the organic layers were combined. LCMS showed reaction was completed. The mixture was added H20 (100 mL) and extracted with EA (100 mL*3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (PE:EA=10: 1) to give ethyl 3-(benzyloxy)-l-methoxycyclobutane-l-carboxylate (4.80 g, 79% yield) as a yellow oil.
Step 3: Synthesis of ethyl 3-hydroxy-l-methoxycyclobutane-l-carboxylate
Palladium hydroxide on carbon (200 mg) was added to a solution of ethyl 3-(benzyloxy)- 1-methoxycyclobutane-l-carboxylate (2.0 g, 7.6 mmol) in EtOH (80 mL) at ambient temperature in a high pressure reaction vessel. The vessel was evacuated and backfilled with hydrogen for three cycles, and was then charged with hydrogen at 50 psi. The reaction mixture was stirred for 16 h at 50 psi, then was evacuated and backfilled with nitrogen. The reaction mixture was filtered, and the filtrate was concentrated to give ethyl 3 -hydroxy- 1-methoxycyclobutane- 1- carboxylate (1.0 g, 76% yield) as a light yellow oil. 1H-NMR (400 MHz, CDC13) δ 4.46-4.42 (m, 1H), 4.27 (q, = 7.2 Hz, 2H), 3.27 (s, 3H), 2.66-2.58 (m, 2H), 2.41-2.34 (m, 2H), 1.33 (t, = 7.2 Hz, 3H).
Step 4: Synthesis of ethyl l-methoxy-3-oxocyclobutane-l-carboxylate
DMP (6.04 g, 14.2 mmol) was added to a solution of ethyl 3-hydroxy-l- methoxycyclobutane-l-carboxylate (1.60 g, 9.19 mmol) in DCM (10 mL) at 20 °C. The reaction mixture was stirred for 16 h, and TLC analysis showed formation of a new spot (PE:EA = 10: 1, Rf = 0.35, stained by I2). The reaction mixture was filtered and the organic phase was concentrated to give crude under reduced pressure. The residue was purified by flash column chromatography on silica gel (PE:EA=10: 1) to give the title compound (1.40 g, 75.2% yield) as a yellow oil.
Example 7. Synthesis of Iodide Intermediates
Ethyl 3-iodo-l-methoxycvclobutane-l-carboxylate
Figure imgf000061_0001
Step 1: Synthesis of ethyl l-methoxy-3-(((trifluoromethyl)sulfonyl)oxy)cyclobutane-l- carboxylate
A solution of ethyl 3 -hydroxy- 1-methoxycyclobutane- 1-carboxylate (29.4 g, 129 mmol) and 2,6-lutidine (29.5 mL, 253 mmol) in DCM (500 mL) was cooled to -10 °C. Trifluoromethanesulfonic anhydride (50 g, 177 mmol) was then added dropwise over 45 min to the cooled solution. The reaction mixture was stirred for 1 h, then was quenched with saturated ammonium chloride solution (500 mL) and the layers were partitioned. The organic layer was dried over sodium sulfate, filtered, and the filtrate was concentrated to give ethyl l-methoxy-3- (((trifluoromethyl)sulfonyl)oxy)cyclobutane-l-carboxylate as a brown oil that was used directly in the next step without any purification.
Step 2: Synthesis of ethyl 3-iodo-l-methoxycyclobutane-l-carboxylate
A solution of the entire crude ethyl l-methoxy-3- (((trifluoromethyl)sulfonyl)oxy)cyclobutane-l-carboxylate from above (assumed to be 169 mmol) in DMF (170 mL) put in a water bath at ambient temperature. Sodium iodide (76 g, 507 mmol) was added to the solution and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with water (1 L) and extracted with ethyl acetate (2 x 400 mL). The organic layers were combined and washed sequentially with water (3 x 1 L), saturated sodium thiosulfate solution, and brine. The organic layer was then dried over sodium sulfate and filtered, and the filtrate was concentrated. The residue was purified by flash-column
chromatography on silica gel (gradient elution, 0 to 20% ethyl acetate-hexanes) to give the title compound (31.5 g, 66% yield over two steps) as a colorless oil. MS (ES+) C8H13IO3 requires: 284, found: 285 [M + H]+. 1H NMR (400 MHz, Chloroform-d) δ 4.33 (p, J = 8.4 Hz, 1H), 4.25 (q, J = 7.1 Hz, 2H), 3.24 (s, 3H), 3.20 - 3.13 (m, 2H), 2.82 - 2.71 (m, 2H), 1.31 (t, J = 7.1 Hz, 3H).
Methyl 3-iodo-l-methylcvclobutane-l-carboxylate
Figure imgf000062_0001
Step 1: Synthesis of methyl l-methyl-3-((methylsulfonyl)oxy)cyclobutane-l-carboxylate
Methanesulfonyl chloride (0.60 mL, 7.6 mmol) was added to a solution of methyl 3- hydroxy-l-methylcyclobutane-l-carboxylate (1.00 g, 6.94 mmol) and triethylamine (1.26 mL, 9.02 mmol) at 0 °C. After the addition, the cooling bath was removed and the reaction mixture was stirred for 70 min. The reaction mixture was then partitioned between DCM and aqueous hydrochloric acid solution (I N). The organic layer was washed with saturated aqueous sodium bicarbonate solution, brine, and then was dried over sodium sulfate. The mixture was then filtered, and the filtrate was concentrated to give methyl l-methyl-3-
((methylsulfonyl)oxy)cyclobutane-l-carboxylate (1.48 g, 96%) as a light yellow oil that was used in the next step without any further purification.
Step 2: Synthesis of methyl 3-iodo-l-methylcyclobutane-l-carboxylate
Sodium iodide (3.79 g, 25.3 mmol) was added to a solution of methyl l-methyl-3- ((methylsulfonyl)oxy)cyclobutane-l-carboxylate (1.41 g, 6.32 mmol) in DMF (12.6 mL). The reaction mixture was heated to 80 °C for 46 h, then was cooled to ambient temperature and partitioned between DCM and water. The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was purified by flash-column chromatography on silica get (gradient elution, 0 to 15% ethyl acetate-hexanes) to give the title compound (659 mg, 41%) as a colorless oil. MS (ES+) C7HnI02 requires: 254, found: 255 [M + H]+.
Example 8. Synthesis of Amine Intermediates
(S)-l-(6-(4-fluoro-lH-pyrazol-l-yl)pyridin-3-yl)ethan-l-amine
Figure imgf000063_0001
Step 1: l-(6-(4-fluoro-lH-pyrazol-l-yl)pyridin-3-yl)ethan-l-one
4-Fluoro-lH-pyrazole (4.73 g, 55 mmol) and potassium carbonate (17.27 g, 125 mmol) were combined and stirred in N,N-dimethylformamide (41.7 mL) for 10 minutes in an open sealed tube before addition of 2-bromo-5-acetylpyridine (10 g, 50 mmol). The reaction tube was sealed and stirred 20 hours at 100°C. The reaction mixture was then cooled to room temperature and poured into water (-700 mL). The mixture was sonicated and stirred for 20 minutes. A beige solid was isolated by filtration, washed with small amounts of water, and dried to yield l-(6-(4- fluoro-lH-pyrazol-l-yl)pyridin-3-yl)ethan-l-one (9.81 g, 96% yield). MS: M+l = 206.0. Step 2: (R)-N-((S)-l-(6-(4-fluoro-lH-pyrazol-l-yl)pyridin-3-yl)ethyl)-2-methylpropane-2- sulfinamide
To a stirred room temperature solution of l-(6-(4-fluoro-lH-pyrazol-l-yl)pyridin-3- yl)ethan-l-one (9.806 g, 47.8 mmol) in THF (96 mL) was added (R)-(-)-t-Butylsulfinamide (5.79 g, 47.8 mmol) followed by titanium (IV) ethoxide (21.8 g, 96 mmol). The solution was stirred at 75°C on an oil bath for 15 hours. The reaction solution was cooled to room temperature and then to -78°C (external temperature) before the next step. To the -78°C solution was added dropwise over nearly 55 minutes L-Selectride (143 mL of IN in THF, 143 mmol). During addition, some bubbling was observed. The reaction was then stirred after the addition was completed for 15 minutes at -78°C before warming to room temperature. LC-MS of sample taken during removal from cold bath showed reaction was completed. The reaction was cooled to -50°C and quenched slowly with methanol (~ 10 mL), then poured into water (600 mL) and stirred. An off-white precipitate was removed by filtration, with ethyl acetate used for washes. The filtrate was diluted with ethyl acetate (800 mL), the layers were separated, and the organic layer was dried over sodium sulfate, filtered, and concentrated down. The crude was purified by silica gel chromatography to yield (R)-N-((S)-l-(6-(4-fluoro-lH-pyrazol-l-yl)pyridin-3-yl)ethyl)-2- methylpropane-2-sulfinamide (10.5 g, 99% purity, 70.3% yield) as a light yellow solid. MS: M+l = 311.1.
Step 3: (S)-l-(6-(4-fluoro-lH-pyrazol-l-yl)pyridin-3-yl)ethan-l-amine
A solution of (R)-N-((S)-l-(6-(4-fluoro-lH-pyrazol-l-yl)pyridin-3-yl)ethyl)-2- methylpropane-2-sulfinamide (10.53 g, 33.9 mmol)) in methanol (79 mmol) and 4N HCl/dioxane (85 mL, 339 mmol) was stirred 2.5 hours. LC-MS showed reaction was completed. The reaction solution was poured into diethyl ether (300 mL). A sticky solid was formed. The mixture was treated with ethyl acetate (200 mL) and sonicated. The solvents were decanted, and the sticky solid was treated with more ethyl acetate (~ 200 mL), sonicated and stirred. The bulk of the sticky solid was converted to a suspension. A light yellow solid was isolated by filtration, washed with smaller amounts of ethyl acetate, and dried to yield (S)-l-(6-(4-fluoro-lH-pyrazol- l-yl)pyridin-3-yl)ethan-l-amine (7.419 g, 78% yield). LC-MS confirmed desired product in high purity. MS: M+l = 207.1. (S)-l-(5-(4-fluoro-lH-pyrazol-l-yl)pyrazin-2-yl)ethan-l-amine
Figure imgf000065_0001
Step 1: l-(5-(4-fluoro-lH-pyrazol-l-yl)pyrazin-2-yl)ethan-l-one
Sodium hydride (60 wt%, 276 mg, 6.90 mmol) was added to a mixture of l-(5- chloropyrazin-2-yl)ethanone (800 mg, 5.11 mmol) and 4-Fluoro-lH-pyrazole (484 mg, 5.62 mmol) in N,N-dimethylformamide (6.0 mL) at ambient temperature for 10 minutes. The reaction mixture was then poured into water (70 mL) and was sonicated and stirred for 20 minutes. A dark red solid was isolated by filtration, washed with small amounts of water, and dried to l-(5- (4-fluoro-lH-pyrazol-l-yl)pyrazin-2-yl)ethan-l-one (919 mg, 95% yield). MS: M+l = 207. Step 2: (R)-N-((S)-l-(5-(4-fluoro-lH-pyrazol-l-yl)pyrazin-2-yl)ethyl)-2-methylpropane-2- sulfinamide
To a stirred room temperature solution of l-(5-(4-fluoro-lH-pyrazol-l-yl)pyrazin-2- yl)ethan-l-one (4.67 g, 22.7 mmol) in THF (45 mL) was added (R)-(-)-t-Butylsulfinamide (2.75 g, 22.7 mmol) followed by titanium (IV) ethoxide (10.3 g, 45.3 mmol). The solution was stirred at 75°C on an oil bath for 20 hours. The reaction solution was cooled to room temperature and then to -78°C before the next step. To the -78°C solution was added dropwise over 50 minutes L- Selectride (50.1 mL of 1 N in THF, 50.1 mmol). During addition, some bubbling was observed. The reaction was then stirred after the addition was completed for 15 minutes at -78°C before warming to room temperature. LC-MS of sample taken during removal from cold bath showed reaction was completed. The reaction was cooled to -60°C and quenched slowly with methanol (1 mL), then poured into water (100 mL) and stirred. The mixture was filtered and the solids were washed further with ethyl acetate. The filtrate was diluted with ethyl acetate, the layers were separated, and the organic layer was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography (gradient elution, 0 to 100% ethyl acetate-dichloromethane) to give (R)-N-((S)- l-(5-(4-fluoro-lH-pyrazol-l-yl)pyrazin-2-yl)ethyl)-2-methylpropane-2-sulfinamide (1.04 g, 14% ) as a brown solid. MS: M+l = 312. 1H NMR (400 MHz, DMSO-i¾) δ 9.12 (d, 7 = 1.4 Hz, 1H), 8.73 (d, 7 = 4.5 Hz, 1H), 8.59 (d, 7 = 1.4 Hz, 1H), 8.03 (d, 7 = 4.1 Hz, 1H),
5.69 (d, 7 = 5.7 Hz, 1H), 4.62 (p, 7 = 6.8 Hz, 3H), 1.57 (d, 7 = 6.9 Hz, 3H), 1.12 (s, 9H).
Step 3: (S)-l-(5-(4-fluoro-lH-pyrazol-l-yl)pyrazin-2-yl)ethan-l-amine
A solution of (R)-N-((S)-l-(5-(4-fluoro-lH-pyrazol-l-yl)pyrazin-2-yl)ethyl)-2- methylpropane-2-sulfinamide (1.04 g, 3.34 mmol) in methanol (7.8 mL) and 4N HCl/dioxane (8.34 mL, 33.4 mmol) was stirred for 1.5 h at ambient temperature. The reaction mixture was poured into diethyl ether (100 mL). A light beige solid was isolated by filtration to afford (S)-l- (5-(4-fluoro-lH-pyrazol-l-yl)pyrazin-2-yl)ethan-l-amine (689 mg, 85% yield). MS: M+l = 208.
(5-(4-fluoro-lH-pyrazol-l-yl)pyrazin-2-yl)methanamine
Figure imgf000066_0001
Step 1: 5-(4-fluoro-lH-pyrazol-l-yl)pyrazine-2-carbonitrile
To a solution of 5-chloropyrazine-2-carbonitrile (280 mg, 2.0 mmol) in DMF was added 4-fluoro-lH-pyrazole (170 mg, 2.0 mmol), and potassium acetate (395 mg, 4.0 mmol). The mixture was stirred at the 100°C for 4 hours. The reaction mixture was cooled to 20°C, poured into brine (25 mL), and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, concentrated and purified by column chromatography (hexane: ethyl acetate = 5: 1) to give 5-(4-fluoro-lH-pyrazol-l-yl)pyrazin-2-carbonitrile (310 mg, Yield 82%). The structure was confirmed by LC-MS.
Step 2: (5-(4-fluoro-lH-pyrazol-l-yl)pyrazin-2-yl)methanamine
A mixture of 5-(4-fluoro-lH-pyrazol-l-yl)pyrazin-2-carbonitrile (190 mg, 1.0 mmol) and NiCl2 (12 mg, 0.1 mmol) in MeOH (5 mL) was added NaBH4 (380 mg, 10 mmol) at 0°C. The mixture was stirred at 0 °C for 2 hours, quenched with aqueous NH4C1 and purified by HPLC to give (5-(4-fluoro-lH-pyrazol-l-yl)pyrazin-2-yl)methanamine (160 mg, Yield 82%). The structure was confirmed by LC-MS.
6-(3,5-dimethyl-lH-pyrazol-l-yl)pyridin-3-yl)methanamine
Figure imgf000067_0001
Step 1: 6-(3,5-Dimethyl-lH-pyrazol-l-yl)nicotinonitrile
To the solution of 6-chloronicotinonitrile (300 mg, 2.2 mmol) in DMF (10 mL), was added 3,5-dimethyl-lH-pyrazole (210 mg, 2.2 mmol ) and Cs2C03 (1.4 g, 4.4 mmol). The mixture was stirred at 90°C for 16 h. Water (25 mL) was added to the reaction mixture, and the mixture was filtered. The solids were washed with water and dried under vacuum to give 6-(3,5- Dimethyl-lH-pyrazol-l-yl)nicotinonitrile (320 mg, yield 74.6%).
Step 2: tert-Butyl ((6-(3,5-dimethyl-lH-pyrazol-l-yl)pyridin-3-yl)methyl)carbamate
To 6-(3,5-Dimethyl-lH-pyrazol-l-yl)nicotinonitrile (300 mg, 1.5 mmol) in MeOH (10 mL), was added NiCl2 (19 mg, 0.15 mmol), (Boc)20 (654 mg, 3.0 mmol) and NaBH4 (142 mg, 3.8 mmol). The mixture was stirred at ambient temperature for 3h. Saturated aqueous ammonium chloride solution was added and the MeOH was removed under vacuum. The aqueous suspension was then partitioned with ethyl acetate, and the layers were separated. The organic layer was washed with saturated sodium bicarbonate solution (2x50mL). The organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated under vacuum to give 450 mg target compound which was used in the next step without further purification.
Step 3: 6-(3,5-Dimethyl-lH-pyrazol-l-yl)nicotinonitrile
A solution of HC1 in Dioxane (4.0 M, 10 mL) was added to compound ie/ -Butyl ((6- (3,5-dimethyl-lH-pyrazol-l-yl)pyridin-3-yl)methyl)carbamate (450 mg). The mixture was stirred for 2h, then was dried under reduced pressure to give the title compound (350 mg) as a light brown solid that was used without further purification. 1H NMR (400 MHz, OMSO-d6) δ 8.51 (d, J =2.1 Hz, 1H), 8.34 (s, 3H), 8.03 (dd, = 8.5, 2.4 Hz, 1H), 7.87 (d, = 8.5 Hz, 1H), 6.14 (s, 1H), 4.12 (q, = 5.7 Hz, 2H), 2.59 (s, 3H), 2.21 (s, 3H).
6-(4-chloro-lH-pyrazol-l-yl)pyridin-3-yl)methanamine
Figure imgf000068_0001
Step 1: 6-(4-Chloro-lH-pyrazol-l-yl)nicotinonitrile
To a solution of 6-chloronicotinonitrile (300 mg, 2.2 mmol) in DMF (10 mL), was added 4-chloro-lH-pyrazole (227 mg, 2.2 mmol) and CS2CO3 (1.4 g, 4.4 mmol). The mixture was stirred at 90 °C for 16 h. Water (25 mL) was added to the mixture, and the mixture was filtered. The solids were washed with water and dried under vacuum to give 6-(4-Chloro- lH-pyrazol-l- yl)nicotinonitrile (380 mg, 84%).
Step 2: tert-Butyl ((6-(4-chloro-lH-pyrazol-l-yl)pyridin-3-yl)methyl)carbamate
To 6-(4-chloro- lH-pyrazol-l-yl)nicotinonitrile (350 mg, 1.7 mmol) in MeOH (10 mL), was added NiCl2 (19 mg, 0.17 mmol), (Boc)20 (741 mg, 3.4 mmol) and NaBH4 (163 mg, 4.3 mmol). The mixture was stirred at ambient temperature, for 3h. Saturated aqueous ammonium chloride solution was added and the MeOH was removed under vacuum. The aqueous suspension was then partitioned with ethyl acetate, and the layers were separated. The organic layer was washed with saturated sodium bicarbonate solution (2x50mL). The organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated under vacuum to give 480 mg target compound, which was used in the next step without further purification.
Step 3: (6-(4-chloro-lH-pyrazol-l-yl)pyridin-3-yl)methanamine
A solution of HC1 in Dioxane (4.0 M, 10 mL) was added to ie/t-Butyl ((6-(4-chloro- lH- pyrazol-l-yl)pyridin-3-yl)methyl)carbamate (450 mg, 1.5 mmol) at ambient temperature. The mixture was stirred for 2h, then was dried under reduced pressure to give the title compound (290 mg) as a light brown solid that was used without further purification. MS: M+1 = 209.
The synthetic protocols that were used to prepare the compounds disclosed herein are indicated below. The NMR and LC MS data obtained for compounds disclosed herein are also shown below.
Table 5.
Figure imgf000069_0001
Compound Synthetic MS
1H NMR
Number Protocol (M+l)
*H NMR (400 MHz, DMSO-d6) δ 11.65 (s, IH), 9.13
(d, / = 1.4 Hz, IH), 8.85 (s, IH), 8.72 (dd, J = 4.6, 0.8
Hz, IH), 8.48 (d, J = 1.4 Hz, IH), 8.36 (d, J = 7.3 Hz,
IH), 8.02 (d, J = 4.1 Hz, IH), 6.90 (s, IH), 6.38 (s, IH),
104 2 476
6.16 (s, IH), 513- 5.06 (m, IH), 3.46 (t, = 7.9 Hz, IH),
3.18- 3.11(m, IH), 3.00 (td, = 6.6, 3.9 Hz, 2H), 2.18
(s, 2H), 2.16 (s, 3H), 1.77 - 1.67 (m, 2H), 1.44 (d, =
7.1 Hz, 3H).
*H NMR (400 MHz, DMSO-d6) δ ppm 11.90 (s, IH),
9.53 (s, IH), 8.67 (d, = 4.5 Hz, IH), 8.39 (d, = 2.1
Hz, IH), 8.31 (d, = 7.7 Hz, IH), 7.96 - 7.81 (m, 3H),
105 3 476
6.87 (s, IH), 6.13 (s, IH), 5.06 - 4.97 (m, IH), 3.50 - 3.40 (m, IH), 3.19 - 3.09 (m, IH), 2.49 - 2.31 (m, 4H),
2.25 (s, 3H), 2.19 (s, 3H), 1.40 (d, = 7.0 Hz, 3H).
1H NMR (400 MHz, DMSO-d6) δ 11.91 (s, IH), 9.56
(s, IH), 8.64 (d, = 4.5 Hz, IH), 8.38 (d, = 2.2 Hz,
IH), 8.03 (d, = 7.9 Hz, IH), 7.99 - 7.79 (m, 3H), 6.80
107 3 490
(s, IH), 6.19 (s, IH), 5.05-4.97 (m, IH), 3.47 (p, = 8.9
Hz, IH), 2.60 (q, = 10.1 Hz, 2H), 2.22 (s, 3H), 2.18 - 2.02 (m, 5H), 1.53 - 1.37 (m, 6H).
1H NMR (400 MHz, DMSO-d6) δ ppm 11.92 (s, IH),
9.56 (s, IH), 8.69 (d, = 4.5 Hz, IH), 8.41 (d, = 2.2
Hz, IH), 8.19 (d, = 7.8 Hz, IH), 8.00 - 7.83 (m, 3H),
108 3 490
6.80 (s, IH), 6.22 (s, IH), 5.13 - 4.98 (m, IH), 3.27 - 3.17 (m, IH), 2.76 - 2.59 (m, 2H), 2.30 - 2.12 (m, 8H),
1.45 (d, = 7.1 Hz, 3H), 1.34 (s, 3H).
1H NMR (400 MHz, DMSO-d6) δ ppm 11.91 (s, IH),
9.55 (s, IH), 9.13 (d, = 1.4 Hz, IH), 8.74 (d, = 4.4
Hz, IH), 8.47 (d, = 1.5 Hz, IH), 8.24 (d, = 7.4 Hz,
110 3 IH), 8.02 (d, = 4.2 Hz, IH), 6.80 (s, IH), 6.21 (s, IH), 491
5.19 - 5.03 (m, IH), 3.28 - 3.18 (m, IH), 2.78 - 2.66
(m, 2H), 2.28 - 2.15 (m, 8H), 1.49 (d, = 7.1 Hz, 3H),
1.36 (s, 3H).
*H NMR (400 MHz, DMSO-d6) δ 11.73 (s, IH), 9.05
(s, IH), 8.67 (d, = 4.5 Hz, IH), 8.49 (d, = 7.7 Hz,
IH), 8.39 (d, = 2.1 Hz, IH), 7.99 - 7.80 (m, 3H), 7.01
1, minor
114 (s, IH), 6.67 (s, IH), 6.14 (s, IH), 5.09 - 4.93 (m, IH), 493 isomer
2.92 (p, J = 9.1, 8.6 Hz, IH), 2.83 - 2.69 (m, 2H), 2.69 - 2.50 (m, 2H), 2.20 (d, = 17.2 Hz, 6H), 1.39 (d, = 6.9
Hz, 3H). Compound Synthetic MS
1H NMR
Number Protocol (M+l)
*H NMR (400 MHz, DMSO-d6) δ 11.74 (s, IH), 8.88
(s, IH), 8.67 (d, J = 4.5 Hz, IH), 8.43 - 8.25 (m, IH),
7.98 - 7.75 (m, 3H), 6.80 (s, IH), 6.76 (s, IH), 6.09 (s,
116 1 505
IH), 5.92 - 5.82 (m, IH), 5.68 (s, IH), 3.38-3.26 (m,
IH), 2.70-2.55 (m, 5 H), 2.25-2.05 (m, 8H), (s, 2H),
2.20 (s, 2H), 2.11 (s, 2H), 1.50 (d, J = 7.1 Hz, 3H).
*H NMR (400 MHz, OMSO-d6) δ 12.83 (s, IH), 11.60
(s, IH), 8.67 (d, J = 4.6 Hz, IH), 8.38 (d, = 2.1 Hz,
IH), 8.33 (d, = 7.7 Hz, IH), 7.92 (dd, / = 8.1, 2.9 Hz,
118 1 2H), 7.86 (d, = 8.5 Hz, IH), 6.89 (s, IH), 6.75 (s, IH), 505
5.92 (s, IH), 3.00 (d, = 13.1 Hz, IH), 2.89 (d, = 13.0
Hz, IH), 2.34 (d, = 13.4 Hz, 2H), 2.28 (s, 3H), 2.25 (s,
3H), 1.58 (s, 3H), 1.43 (d, = 7.1 Hz, 3H).
1H NMR (400 MHz, DMSO-d6) δ ppm 11.68 (s, IH),
8.87 (s, IH), 8.67 (d, = 4.5 Hz, IH), 8.44 (d, = 2.2
Hz, IH), 8.18 (d, = 7.8 Hz, IH), 8.04 - 7.94 (m, IH),
119 1 7.94 - 7.80 (m, 2H), 6.79 (s, IH), 6.70 (s, IH), 6.29 (s, 505
IH), 5.46 (s, IH), 5.15 - 4.97 (m, IH), 2.55 (s, 4H),
2.25 - 2.12 (m, 6H), 1.45 (d, = 7.1 Hz, 3H), 1.35 (s,
3H).
1H NMR (400 MHz, DMSO-d6) δ 11.68 (s, IH), 8.94
(s, IH), 8.67 (d, = 4.5 Hz, IH), 8.51 (d, = 8.3 Hz,
IH), 8.45 (d, = 2.2 Hz, IH), 8.00 (dd, / = 8.6, 2.3 Hz,
120 2 IH), 7.94 - 7.85 (m, 2H), 6.80 (s, IH), 6.40 (s, IH), 505
6.27 (s, IH), 5.21 - 4.94 (m, IH), 3.19 - 3.00 (m, 4H),
2.70 - 2.35 (m, 4H), 2.17 (d, = 6.7 Hz, 6H), 1.48 (d,
= 7.0 Hz, 3H).
*H NMR (400 MHz, DMSO-d6) δ 11.93 (s, IH), 9.61
(s, IH), 8.67 (d, = 4.5 Hz, IH), 8.49 (d, = 8.2 Hz,
IH), 8.44 (d, = 2.2 Hz, IH), 8.00 (dd, = 8.5, 2.3 Hz,
121 3 506
IH), 7.93 - 7.85 (m, 2H), 6.84 (s, IH), 6.20 (s, IH),
5.16 - 5.01 (m, IH), 3.10 (s, 4H), 2.69 - 2.39 (m, 4H),
2.24 (s, 3H), 2.19 (s, 3H), 1.47 (d, = 7.1 Hz, 3H).
*H NMR (400 MHz, DMSO-d6) δ 11.90 (s, IH), 9.66 - 9.48 (m, IH), 9.13 (d, = 1.3 Hz, IH), 8.73 (d, = 4.5
Hz, IH), 8.54 (d, = 1.3 Hz, IH), 8.41 (d, = 7.8 Hz,
123 3 IH), 8.02 (d, = 4.1 Hz, IH), 6.84 (s, IH), 6.21 (s, IH), 507
5.29 - 5.12 (m, IH), 3.23 - 3.08 (m, 4H), 2.70 - 2.43
(m, 4H), 2.24 (s, 3H), 2.19 (s, 3H), 1.51 (d, = 7.1 Hz,
3H). Compound Synthetic MS
1H NMR
Number Protocol (M+l)
*H NMR (400 MHz, DMSO-d6) δ 11.77 (s, 1H), 9.24
(s, 1H), 9.13 (d, 7 = 1.4 Hz, 1H), 8.73 (d, 7 = 4.5 Hz,
1H), 8.54 (d, 7 = 1.4 Hz, 1H), 8.44 (d, 7 = 7.9 Hz, 1H),
124 2 507
8.02 (d, 7 = 4.1 Hz, 1H), 6.54 (s, 2H), 5.25 - 5.06 (m,
1H), 3.17 (s, 4H), 2.71 - 2.37 (m, 4H), 2.26 (s, 3H),
2.19 (s, 3H), 1.51 (d, 7 = 7.0 Hz, 3H).
1H NMR (400 MHz, DMSO-i¾) δ 10.04 - 9.91 (m,
1H), 8.62 (d, 7 = 4.4 Hz, 1H), 8.32 (s, 2H), 7.91 (d, 7 =
4.1 Hz, 1H), 7.84 (s, 1H), 7.79 (d, 7 = 8.5 Hz, 1H), 6.80
126 1 (s, 1H), 6.74 (s, 1H), 6.14 (s, 1H), 5.09 - 5.04 (m, 1H), 507
3.28-3.22 (m, 1H), 3.14-3.08 (m, 1H), 2.40-2.36 (m,
1H), 2.25 (s, 3H), 2.21 (s, 3H), 2.04-1.96 (m, 1H), 1.61
(s, 3H).
1H NMR (400 MHz, DMSO-d6) δ 11.67 (s, 1H), 8.99
(s, 1H), 8.72 (d, 7 = 8.1 Hz, 1H), 8.68 (d, 7 = 4.5 Hz,
1H), 8.46 (d, 7 = 2.2 Hz, 1H), 8.02 (dd, 7 = 8.5, 2.3 Hz,
127 1 1H), 7.94 - 7.85 (m, 2H), 6.73 (s, 1H), 6.46 (s, 1H), 5.81 521
(s, 1H), 5.21 - 5.08 (m, 1H), 3.16 (s, 3H), 2.93 (t, 7 =
11.9 Hz, 2H), 2.49 (s, 3H), 2.45 - 2.34 (m, 2H), 2.18 (s,
3H), 1.50 (d, 7 = 7.1 Hz, 3H).
1H NMR (400 MHz, DMSO-d6) δ 11.61 (s, 1H), 8.80
(s, 1H), 8.63 (d, 7 = 4.5 Hz, 1H), 8.37 (t, 7 = 4.1 Hz,
2H), 7.94 - 7.86 (m, 2H), 7.82 (d, 7 = 8.5 Hz, 1H), 6.80
128 1 521
(s, 1H), 6.66 (s, 1H), 6.22 (s, 1H), 5.50 (s, 1H), 5.06 - 4.99 (m, 1H), 3.14 - 3.03 (m, 5H), 2.32 - 2.25 (m, 2H),
2.14 (s, 3H), 2.13 (s, 3H), 1.42 (d, 7 = 7.0 Hz, 3H).
1H NMR (400 MHz, DMSO-d6) δ 11.77 (s, 1H), 9.24
(s, 1H), 9.12 (d, 7 = 1.4 Hz, 1H), 8.72 (d, 7 = 4.5 Hz,
1H), 8.65 (t, 7 = 6.0 Hz, 1H), 8.44 (d, 7 = 1.4 Hz, 1H),
131 2 493
8.02 (d, 7 = 4.1 Hz, 1H), 6.55 (s, 2H), 4.53 (d, 7 = 5.9
Hz, 2H), 3.22 - 3.14 (m, 4H), 2.67-2.42 (m, 4H), 2.27
(s, 3H), 2.19 (s, 3H).
Example 9: Measurement of Biochemical Activity of Compounds
In order to assess the activity of chemical compounds against the relevant kinase of interest, the Caliper LifeSciences electrophoretic mobility shift technology platform is used. Fluorescently labeled substrate peptide is incubated in the presence of kinase and ATP so that a reflective proportion of the peptide is phosphorylated. At the end of the reaction, the mix of phosphorylated (product) and non-phosphorylated (substrate) peptides are passed through the microfluidic system of the Caliper EZ Reader 2, under an applied potential difference. The presence of the phosphate group on the product peptide provides a difference in mass and charge between those of the substrate peptide, resulting in a separation of the substrate and product pools in the sample. As the pools pass a LEDS within the instrument, these pools are detected and resolved as separate peaks. The ratio between these peaks therefore reflects the activity of the chemical matter at that concentration in that well, under those conditions.
RET wild type assay at KM
In each well of a 384-well plate, 7.5 nM - 10 nM of wild type RET (ProQinase 1090- 0000-1) is incubated in a total of 12.5 of buffer (100 mM HEPES pH 7.5, 0.015% Brij 35, 10 mM MgCl2, ImM DTT) with 1 μΜ CSKtide (FITC - AHA- KKKKD DIYFFFG-NH2) (SEQ ID NO: 5) and 25 μΜ ATP at 25°C for 120 minutes in the presence or absence of a dosed concentration series of compound (1% DMSO final concentration). The reaction is stopped by the addition of 70 μΐ, of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij 35, 35 mM EDTA and 0.2% of Coating Reagent 3 (Caliper Lifesciences)). The plate is then read on a Caliper EZReader 2 (protocol settings: -1.7 psi, upstream voltage -500, downstream voltage -3000, post sample sip 35s). Data is normalized to 0% and 100% inhibition controls and the IC50 calculated using a 4-parameter fit in the CORE LIMS.
RET V804L Gatekeeper mutant assay at KM
In each well of a 384-well plate, 7.5 nM - 10 nM of mutant RET (ProQinase 1096-0000- 1) is incubated in a total of 12.5 of buffer (100 mM HEPES pH 7.5, 0.015% Brij 35, 10 mM MgC12, ImM DTT) with 1 μΜ CSKtide (FITC-AHA-KKKKDDIYFFFG-NH2) (SEQ ID NO: 5) and 10 μΜ ATP at 25°C for 120 minutes in the presence or absence of a dosed concentration series of compound (1% DMSO final concentration). The reaction is stopped by the addition of 70 μΐ, of Stop buffer (100 mM HEPES pH 7.5, 0.015% Brij 35, 35 mM EDTA and 0.2% of Coating Reagent 3 (Caliper Lifesciences)). The plate is then read on a Caliper EZReader 2 (protocol settings: -1.7 psi, upstream voltage -500, downstream voltage -3000, post sample sip 35s). Data is normalized to 0% and 100% inhibition controls and the IC50 calculated using a 4- parameter fit in the CORE LIMS.
In Table 6 below, the following designations are used: < 1.00 nM = A; 1.01-10 nM = B; 10.01-100 nM = C; < 100 nM=D; and ND = not determined.
Table 6. RET Inhibitory Activity of Exemplary Compounds of the Invention.
Figure imgf000074_0002
Figure imgf000074_0001
Example 10: Compounds of Structural Formula (I) are potent inhibitors of wild-type and mutant
RET In embodiments, compounds according to structural Formula (I) and structural Formula (II) are potent and selective inhibitors of oncogenic RET mutant and fusion proteins. Currently, there are no approved inhibitors that selectively target these disease-driving RET alterations.
1. In vitro assays
A compound described herein can be tested in vitro for inhibition of wild-type RET and various mutant RET kinases, including e.g., RET V804L, RET V804M, and RET M918T kinases, as well as CCDC6-RET and KIF5B-RET fusion kinases. The IC50 can be calculated.
2. Cellular assays
In cellular systems, the activity of a compound of structural Formula (I) or structural Formula (II) can be measured by inhibition of RET mutant or RET fusion autophosphorylation, RET- dependent signaling, and by inhibition of RET dependent cell proliferation. The compound can be assayed for activity in cancer cell lines endogenously expressing activated RET fusions or mutants. Exemplary cells that can be used for these studies include patient xenografts and established cell lines. Exemplary patient xenografts include Colorectal Cancer patient derived xenograft, Lung adenocarcinoma patient derived xenograft, and NSCLC patient derived xenograft. Exemplary cell lines include Ba/F3-KIF5B-RET (a model for leukemia), LC2/ad cells (a model for lung cancer), MZ-CRC 1 (a model for thyroid cancer), and TT cells (a medullary thyroid cancer cell line). Exemplary RET mutations that can be used for these studies include fusions such as KIF5B-RET and CCDC6-RET; point mutations such as RET C634W, RET V804L, RET V804E, RET V804M, and RET M918T; and fusions containing point mutations such as KIF5B-RET (V804L) and KIF5B-RET (V804M). KIF5B-RET (V804L) refers to a mutant RET that comprises a fusion with KIF5B and further comprises a V804L mutation in RET (referring the amino acid numbering of wild-type RET). KIF5B-RET (V804M) refers to a mutant RET that comprises a fusion with KIF5B and further comprises a V804M mutation in RET. 2a. Autophosphorylation assays
As an example of an autophosphorylation assay, in Ba/F3 models engineered to express KIF5B RET, the compound is tested for its ability to inhibit RET fusion protein signaling as measured by inhibition of RET autophosphorylation. IC50 can be calculated. Wild-type RET inhibitors cabozantinib and vandetanib can be used as controls (less potent compounds than the test compound) in these cellular assays. In embodiments, the compound of structural Formula (I) and (II) potently and selectively inhibit RET autophosphorylation.
The compound can also be tested for ability to inhibit RET autophosphorylation in LC2/ad cells, a non-engineered NSCLC cell line that expressed a CCDC6-RET fusion (Suzuki et al, 2013). For instance, immunoblot is performed for LC2/ad cells expressing the CCDC6-RET fusion protein and treated with the test compound at different concentrations; Phosphorylated
(phospho[Y1062]) and total protein levels of RET are measured.
2b. Proliferation assays
In embodiments, the compound of structural Formula (I) and (II) inhibits proliferation.
In proliferation assays, the compound can be tested for ability to inhibit KIF5B-RET dependent Ba/F3 cell growth. The IC50 can be calculated.
Inhibition of RET activity with the compound can also be tested for inhibition of proliferation of the CCDC6-RET expressing cell line. Similarly, the compound can also be tested for its ability to inhibit RET pathway signaling and RET dependent proliferation in the human MTC TT and MZ-CRC 1 cell lines, driven by RET C634W or RET M918T mutations, respectively. In some embodiments, in RET-driven cell lines, the test compound inhibits RET activity and RET-driven proliferation more potently than the multi-kinase inhibitors such as cabozantinib and vandetanib.
2c. Downstream signalling assays
In LC2/ad cells, a non-engineered NSCLC cell line that expressed a CCDC6-RET fusion (Suzuki et al, 2013), the compound can be tested for its ability to inhibit phosphorylation of the RET substrate Src homology domain (She) (Hayashi et al, 2000), and downstream signaling through extracellular signal regulated kinase (ERK)l/2, including downregulation of dual specificity phosphatase 6 (DUSP6) and sprouty receptor tyrosine kinase signaling antagonist 4 (SPRY4) (Lito et al, 2013). For instance, immunoblot can be performed for LC2/ad cells expressing the CCDC6-RET fusion protein and treated with the test compound at different concentrations; phosphorylated and total levels of downstream biomarkers, e.g., phospho(Y239/Y240)-Shc and phospho(Y202/T204)-ERKl/2, are measured. In addition, to determine expression levels of downstream targets, LC2/ad cells can be treated with the compound, cabozantinib, or DMSO for 7 hours and RNA is harvested. Gene expression levels of DUSP6 and SPRY4 can be measured by qRT-PCR. In embodiments, the compound induces a dose-dependent decrease in expression of the ERK1/2 target genes DUSP6 and SPRY4 but not the control gene glycogen synthase kinase 3 beta (GSK3B).
3. Animal models
Antitumor efficacy of compounds of structural Formula (I) and (II) can be demonstrated in several RET-driven in vivo models. The Ba/F3-KIF5B-RET allograft model uses KIF5B RET fusion-dependent Ba/F3 cells. The test compound can be administered orally with an appropriate dose. Tumor size can be measured e.g., twice weekly. In embodiments, administration of the compound results in robust and dose-dependent growth inhibition of Ba/F3-KIF5B-RET allograft tumors, e.g., in complete TGI and Mouse body weight can be measured e.g., twice- weekly during the administration. In embodiments, the compound is well tolerated with no significant changes in animal body weight observed.
Similar assays can be performed using other animal models, including a Ba/F3-KIF5B-RET (V804L) allograft tumor model which comprises a KIF5B RET V804L fusion protein, an KIF5B-RET NSCLC allograft tumor model, an MTC cell line xenograft driven by a RET C634W mutation, and a CCDC6-RET fusion positive colorectal cancer allograft tumor model. The RET V804L mutation has been observed in rare cases of MTC and is predicted to be insensitive to cabozantinib and vandetanib in vitro and in vivo (Carlomagno et al, 2004; Bentzien et al, 2013; BPM 0016). In embodiments, the compound causes complete TGI and regressions in a cancer that is not responsive to cabozantinib or vandetanib. Biochemical markers can also be assayed in the treated mice. To assess direct inhibition of KIF5B-RET (V804L) fusion kinase activity in Ba/F3 KIF5B-RET (V804L) tumors, the compound can be administered orally at an appropriate dose to tumor bearing mice for several days and plasma and tumors can be collected from individual mice at appropriate time points after the last dose. Test compound concentrations in plasma can be determined by liquid chromatograph/tandem mass spectrometry (LC/MS/MS). Inhibition of KIF5B-RET (V804L) signaling in the tumor tissue can be assessed by a phosphor RET enzyme linked immunosorbent assay (ELISA) and by immunoblotting, e.g., as described above. Quantitation of the phospho- RET signal by ELISA can measure the percent KIF5B-RET (V804L) inhibition in treated animals as compared to vehicle treated controls. Suppression of downstream RET pathway signaling can be demonstrated by inhibition of She phosphorylation. In embodiments, a dose and time-dependent correlation is observed between the concentration of the test compound in mouse plasma and the level of phosphorylated KIF5B RET (V804L). In embodiments, administration of the compound at an amount sufficient to reach at least 90% inhibition of RET in vivo leads to therapeutic efficacy, e.g., can lead to 100% tumor growth inhibition.
Example 11: Selectivity of Compounds of Structural Formulas (I) and (II) Efficacy against wild-type and mutant RET
In embodiments, compounds according to structural Formula (I) and structural Formula (II) are potent inhibitors of wild-type and mutant RET. For instance the IC50 of a compound can be tested in a cell line comprising wild-type RET and in a second cell line comprising mutant RET, e.g., a point mutation or fusion.
Selectivity for RET over KDR
In embodiments, compounds according to structural Formula (I) and structural Formula (II) are selective for RET over another kinase, such as KDR (also called Vascular endothelial growth factor receptor 2). KDR is a tyrosine -protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Inhibition of KDR/VEGFR2 has been associated clinically with certain adverse effects, e.g. , hypertension, arterial thrombosis, and hemorrhage, and therefore selectivity for RET over KDR is desirable.
To test selectivity, the test compound can be assayed for its ability to inhibit proliferation in parental Ba/F3 cells that do not express a RET mutation, e.g. , does not express a KIF5B-RET fusion. A weak IC50 in the parental cell line indicates that the test compound is selective for cell lines dependent on oncogenic RET.
The selectivity of a compound on RET versus other human kinases can be characterized by profiling binding across a panel of over 450 human kinases and disease-relevant kinase mutants. In embodiments, the compound has a high degree of selectivity for RET and RET kinase mutants over other kinases tested. To define the binding affinity for the kinases bound by the compound in kinome screening and additional kinases of interest, the dissociation constant (Kd) can be determined.
To differentiate the compound from multi-kinase inhibitors with biochemical activity against RET, the activity of the compound against recombinant kinase insert domain receptor (KDR) (also known as vascular endothelial growth factor receptor 2 [VEGFR2]) and fibroblast growth factor receptor 1 (FGFR1) can be tested, as inhibition of these kinases is associated with dose- limiting toxicities in humans. Inhibition of KDR/VEGFR2 has been associated clinically with hypertension, arterial thrombosis, and hemorrhage, whereas inhibition of fibroblast growth factor receptors (FGFRs) is associated with hyperphosphatemia and tissue calcification (Abdel-Rahman and Fouad, 2014; Touat et al, 2015). In embodiments, the compound is a more potent inhibitor of WT RET than KDR/VEGFR2 and FGFR1, respectively. In contrast, in embodiments a multi- kinase inhibitor exhibits approximately equal or increased potency on KDR versus WT RET.
Example 12: Selective compounds prevent RET resistance mutants
The compounds herein can be tested for the propensity of a cancer to develop one or more RET mutations associated with drug resistance. For example, RET-altered cancer cells (e.g. , Ba/F3 KIF5B-RET cells) can be treated with a mutagen such as ENU, exposed to a compound herein or a control compound (e.g. , for 2-3 weeks), and the cell number can be quantified. Cells with high proliferation can be subjected to DNA sequencing to detect RET mutations. In embodiments, a compound of structural Formula (I) or (II) leads to no or fewer RET mutations than a control compound such as a multi-kinase inhibitor such as cabozantinib.
Incorporation by Reference
All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.
Equivalents
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims

Claims:
1. A com ound having the structural Formula (I):
Figure imgf000081_0001
(I), or a pharmaceutically acceptable salt thereof, wherein:
ring A is an aryl or heteroaryl ring;
each of X1 and X2 is independently selected from N and C(R6);
1 7
each R and each R is independently selected from selected from Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Ci-C6 alkoxy, halo, Ci-C6 heteroalkyl, cycloalkyl, aryl, heteroaryl, aryloxy, aralkyl, heterocyclyl, heterocyclylalkyl, nitro, cyano, -C(0)R, -OC(0)R, - C(0)OR, -(Ci-Ce alkylene)-C(0)R, -SR, -S(0)2R, -S(0)2-N(R)(R), -(Ci-C6 alkylene)- S(0)2R, -(Ci-C6 alkylene)-S(0)2-N(R)(R), -N(R)(R), -C(0)-N(R)(R), -N(R)-C(0)R, -N(R)- C(0)OR, -(Ci-C6 alkylene)-N(R)-C(0)R, -N(R)S(0)2R, and -P(0)(R)(R); wherein each of alkyl, alkenyl, alkynyl, alkoxy, heteroalkyl, cycloalkyl, aryl, heteroaryl, aryloxy, aralkyl, heterocyclyl, and heterocyclylalkyl is independently substituted with 0-5 occurrences of Ra; or two R1 or two R are taken together with the carbon atoms to which they are attached form a cycloalkyl or heterocyclyl ring independently substituted with 0-5 occurrences of Rb;
each of R2, R3a, R3b, R4, R8a and R8b is independently selected from hydrogen, Ci-C6 alkyl, Ci-C6 alkoxy, halo, hydroxyl, Ci-C6 heteroalkyl, and -N(R)(R); wherein each alkyl, alkoxy, and heteroalkyl is optionally and independently substituted with 0-5 occurrences of Ra; each of R5 and R9 is independently selected from hydrogen, Ci-C6 alkyl, and Ci-C6 heteroalkyl; wherein each alkyl and heteroalkyl is optionally and independently substituted with 0-5 occurrences of Ra;
each R6 is independently selected from hydrogen, Ci-C6 alkyl, Ci-C6 alkoxy, halo, Ci-C6 heteroalkyl, and -N(R)(R); wherein each alkyl, alkoxy, and heteroalkyl is optionally and independently substituted with 0-5 occurrences of Ra;
each R is independently selected from hydrogen, hydroxyl, halo, thiol, Ci-C6 alkyl, Ci-C6 thioalkyl, Ci-C6 alkoxy, Ci-C6 heteroalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, wherein each of alkyl, thioalkyl, alkoxy, heteroalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl is independently substituted with 0-5 occurrences of Ra, or two R together with the atom(s) to which they are attached form a cycloalkyl or heterocyclyl ring independently substituted with 0-5 occurrences of
Rb;
each Ra and each Rb is independently selected from Ci-C6 alkyl, halo, hydroxyl, Ci-C6 heteroalkyl, Ci-C6 alkoxy, cycloalkyl, heterocyclyl, or cyano, wherein each of alkyl, heteroalkyl, alkoxy, cycloalkyl and heterocyclyl is independently substituted with 0-5 occurrences of R'; each R' is independently selected from Ci-C6 alkyl, Ci-C6 heteroalkyl, halo, hydroxyl, cycloalkyl or cyano; or two R together with the atom(s) to which they are attached form a cycloalkyl or heterocyclyl ring;
m is 0, 1, or 2; and
n is 0, 1, 2, or 3.
2. The compound of claim 1, wherein m is 1; R1 is located at the 5-position; and R1 is Ci-C4 alkyl substituted with 0-3 occurrences of Ra.
3. The compound of claim 2, wherein R1 is -CH3.
4. The compound of any of claims 1-3, wherein R is selected from hydrogen, hydroxyl, halo and 0-Ci-C4 alkyl.
5. The compound of claim 4, wherein R is selected from hydrogen, hydroxyl, fluoro and -OCH3.
6. The compound of any one of claims 1-5, wherein each of R3a, R3b, R8a and R8b is hydrogen.
7. The compound of any one of claims 1-6, wherein R4 is selected from hydrogen, Ci-C4 alkyl and 0-Ci-C4 alkyl, wherein each alkyl portion of R4 is substituted with 0-3 occurrences of Ra.
8. The compound of claim 7, wherein R4 is selected from hydrogen, -CH3, and -OCH3.
9. The compound of any one of claims 1-8, wherein R5 is selected from hydrogen, Ci-C4 alkyl substituted with 0-3 occurrences of Ra.
10. The compound of claim 9, wherein R5 is selected from hydrogen and -CH3.
11. The compound of any one of claims 1-10, wherein each R6 is independently selected from hydrogen, halo, and Ci-C4 alkyl substituted with 0-3 occurrences of Ra.
12. The compound of claim 11, wherein each R6 is independently selected from hydrogen, chloro and -CH3.
13. The compound of claim 12, wherein no more than one R6 is other than hydi
14. The compound of any one of claims 1-13, wherein ring A is a 6-membered monocyclic heteroaryl comprising at least one nitrogen ring atom.
Figure imgf000083_0001
15. The compound of claim 14, wherein ring A is selected from and
Figure imgf000083_0002
The compound of any one of claims 1-15, wherein n is 1; and R is pyrazol-l-yl substituted with 0-3 occurrences of Rb.
17. The compound of claim 16, wherein R is selected from 4-fluoropyrazol-l-yl and pyrazol-l-yl.
The compound of any one of claims 1-17, wherein R9 is selected from hydrogen and
C4 alkyl substituted with 0-3 occurrences of Ra.
The compound of claim 18, wherein R9 is selected from hydrogen and methyl.
The com ound of claim 1 having the structural Formula (la):
Figure imgf000084_0001
(la) or a pharmaceutically acceptable salt thereof,
wherein ring A, X1, X2, R1, R2, R3a, R3b, R4, R5, R6, R7, R8a, R8b, R9, m and n are as defined as for structural Formula (I).
21. The compound of claim 1 having the structural Formula (lb):
Figure imgf000085_0001
(lb) or a pharmaceutically acceptable salt thereof, wherein ring A, X1, X2, R1, R2, R3a, R3b, R4, R5, R6, R7, R8a, R8b, R9, m and n are as defined as for structural Formula (I).
A compound having the structural Formula (II)
Figure imgf000085_0002
(II), or a pharmaceutically acceptable salt thereof, wherein:
X1 is selected from N, CH and C(halo);
X is selected from N and CH;
X is selected from N and CH;
R 12 is selected from hydrogen, hydroxyl, halo and optionally substituted 0-Ci-C4 alkyl; R14 is selected from hydrogen, optionally substituted -Ci-C4 alkyl and optionally substituted -0-Ci-C4 alkyl;
R15 is selected from hydrogen and optionally substituted -Ci-C4 alkyl;
R16 is selected from hydrogen and optionally substituted -Ci-C4 alkyl;
R 17 is selected from hydrogen and halo; and R is selected from hydrogen and optionally substituted -Ci-C4 alkyl.
23. The compound of claim 22, wherein:
X1 is selected from N, CH and C(C1);
X is selected from N and CH;
X is selected from N and CH;
R 12 is selected from hydrogen, hydroxyl, fluoro and -0-CH3;
R14 is selected from hydrogen, -CH3, and -OCH3;
R15 is selected from hydrogen and -CH3;
R16 is selected from hydrogen and -CH3;
R 17 is selected from hydrogen and fluoro; and
R19 is selected from hydrogen and -CH3.
24. The compound of claim 23, wherein when X1 is CH, R16 is -CH3.
25. The compound of claim 22 having the structural Formula (Ila):
Figure imgf000086_0001
(Ila) or a pharmaceutically acceptable salt thereof, wherein X1, X2, X3, R12, R14, R15, R16, R17a, R17b, R17c, R18a, R18b and R19 are as defined as for structural Formula (II). The compound of claim 22, having the structural Formula (lib)
Figure imgf000087_0001
or a pharmaceutically acceptable salt thereof,
wherein X1, X2, X 33,
Figure imgf000087_0002
R15, R16, R17a, R17b, R17c, R18a, R18b and R19 are as defined as for structural Formula (II).
27. A pharmaceutical composition comprising a compound of any one of claims 1 to 26; and a pharmaceutically acceptable carrier.
28. A method for inhibiting RET activity in a cell or in a patient, comprising the step of contacting the cell or administering to the patient a compound of any one of claims 1 to 26 or a pharmaceutical composition of claim 27.
29. A method for treating a subject suffering from a condition mediated by aberrant RET activity, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 26 or a pharmaceutical composition of claim 27.
30. A method for treating a subject who has developed resistance to a cancer treatment, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 26 or a pharmaceutical composition of claim 27.
The method of claim 30, wherein the subject has developed resistance to a wild-type RET
32. A method of treating cancer in a subject, said method comprising:
a. determining if, having determined if, or receiving information that the subject has a RET-altered cell, cancer, gene, or gene product, e.g. , has a fusion or point mutation;
b. identifying the patient as responsive to a compound of any of claims 1-26 when the subject has the RET-altered cell, cancer, gene, or gene product; and c. administering an effective amount of the compound to the subject.
33. A compound of any one of claims 1 to 26 or a pharmaceutical composition of claim 27 for use in inhibiting RET activity in a cell or in a patient.
34. A compound of any one of claims 1 to 26 or a pharmaceutical composition of claim 27 for use in treating a subject suffering from a condition mediated by aberrant RET activity.
35. A compound of any one of claims 1 to 26 or a pharmaceutical composition of claim 27 for use in treating a subject who has developed resistance to a cancer treatment.
36. The compound or pharmaceutical composition for the use according to claim 35, wherein the subject has developed resistance to a wild-type RET inhibitor.
37. A compound of any one of claims 1 to 26 for use in a method of treating cancer in a subject, said method comprising:
a. determining if, having determined if, or receiving information that the subject has a RET- altered cell, cancer, gene, or gene product, e.g. , has a fusion or point mutation;
b. identifying the patient as responsive to a compound of any of claims 1-26 when the
subject has the RET-altered cell, cancer, gene, or gene product; and
c. administering an effective amount of the compound to the subject.
PCT/US2017/022969 2016-03-17 2017-03-17 Inhibitors of ret receptor tyrosine kinases WO2017161269A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662309748P 2016-03-17 2016-03-17
US62/309,748 2016-03-17

Publications (1)

Publication Number Publication Date
WO2017161269A1 true WO2017161269A1 (en) 2017-09-21

Family

ID=58428429

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/022969 WO2017161269A1 (en) 2016-03-17 2017-03-17 Inhibitors of ret receptor tyrosine kinases

Country Status (5)

Country Link
US (1) US10183928B2 (en)
AR (1) AR107912A1 (en)
TW (1) TW201738228A (en)
UY (1) UY37155A (en)
WO (1) WO2017161269A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018213329A1 (en) 2017-05-15 2018-11-22 Blueprint Medicines Corporation Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2020033838A2 (en) 2018-08-10 2020-02-13 Blueprint Medicines Corporation Treatment of egfr-mutant cancer
WO2020035065A1 (en) * 2018-08-17 2020-02-20 南京明德新药研发有限公司 Pyrazole derivative as ret inhibitor
US10584114B2 (en) 2015-11-02 2020-03-10 Blueprint Medicines Corporation Inhibitors of RET
WO2020083311A1 (en) * 2018-10-24 2020-04-30 南京明德新药研发有限公司 Pyrazine derivative as ret inhibitor
CN111285882A (en) * 2018-12-07 2020-06-16 四川科伦博泰生物医药股份有限公司 Fused ring compound, pharmaceutical composition containing same, and preparation method and application thereof
CN111285875A (en) * 2018-12-06 2020-06-16 苏州信诺维医药科技有限公司 Heterocyclic compound, application thereof and pharmaceutical composition containing same
CN111484479A (en) * 2019-01-25 2020-08-04 四川科伦博泰生物医药股份有限公司 Nitrogen heterocyclic compound, pharmaceutical composition containing nitrogen heterocyclic compound, preparation method and application of nitrogen heterocyclic compound
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020200314A1 (en) * 2019-04-03 2020-10-08 南京明德新药研发有限公司 Nitrogen-containing spiro derivative as ret inhibitor
WO2020207419A1 (en) 2019-04-12 2020-10-15 浙江海正药业股份有限公司 Piperazine amide derivative, preparation method therefor, and use thereof in medicine
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN113135896A (en) * 2020-01-18 2021-07-20 正大天晴药业集团股份有限公司 Methylpyrazole derivatives as RET inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113784963A (en) * 2019-05-20 2021-12-10 浙江同源康医药股份有限公司 Compounds useful as RET kinase inhibitors and uses thereof
US11273160B2 (en) 2018-04-03 2022-03-15 Blueprint Medicines Corporation RET inhibitor for use in treating cancer having a RET alteration
WO2023239422A2 (en) 2021-10-22 2023-12-14 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
WO2024022206A1 (en) * 2022-07-23 2024-02-01 浙江海正药业股份有限公司 Crystal form of piperazine amide derivative, preparation method therefor and use thereof

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3205654T (en) 2010-05-20 2019-05-27 Array Biopharma, Inc. Macrocyclic compounds as trk kinase inhibitors
SG11201500125QA (en) 2012-07-11 2015-02-27 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
AU2014337314B2 (en) 2013-10-17 2018-12-13 Blueprint Medicines Corporation Compositions useful for treating disorders related to KIT
US9434700B2 (en) 2013-10-25 2016-09-06 Neil Bifulco, JR. Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
AU2016297754A1 (en) 2015-07-24 2018-02-15 Blueprint Medicines Corporation Compounds useful for treating disorders related to KIT and PDGFR
CA2995997A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
CN108431008A (en) 2015-11-19 2018-08-21 蓝图药品公司 It can be used for treating the compound and composition with the relevant illnesss of NTRK
EP4285996A3 (en) 2016-04-15 2024-01-10 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
TW202410896A (en) 2017-10-10 2024-03-16 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
JP7278273B2 (en) 2017-10-18 2023-05-19 ブループリント メディシンズ コーポレイション Substituted pyrrolopyridines as inhibitors of activin receptor-like kinases
TWI802635B (en) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN110294745B (en) * 2018-03-22 2022-04-19 浙江海正药业股份有限公司 Five-membered heterocyclic derivative, preparation method and medical application thereof
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
WO2020083332A1 (en) * 2018-10-24 2020-04-30 南京明德新药研发有限公司 Pyrimidine derivative acting as ret inhibitor
CN111499613B (en) * 2019-01-31 2023-05-12 浙江海正药业股份有限公司 N-carboxamide derivatives, method for the production thereof and their use in medicine
FI3856341T3 (en) 2019-04-12 2023-11-30 Blueprint Medicines Corp Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
TWI777509B (en) 2020-04-27 2022-09-11 美商美國禮來大藥廠 Compounds useful for inhibiting ret kinase
CN116438179A (en) 2020-11-06 2023-07-14 伊莱利利公司 Pyrazole derivatives as RET kinase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039971A1 (en) * 2012-09-07 2014-03-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
WO2014072220A1 (en) * 2012-11-07 2014-05-15 Nerviano Medical Sciences S.R.L. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
CA2493000A1 (en) 2002-07-24 2004-01-29 University Of Cincinnati 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases
US20100047777A1 (en) 2005-05-26 2010-02-25 The Johns Hopkins University Methods for identifying mutations in coding and non-coding dna
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
US20090012045A1 (en) 2007-06-26 2009-01-08 Rigel Pharmaceuticals, Inc. Methods of Treating Cell Proliferative Disorders
EA201000092A1 (en) 2007-07-09 2010-06-30 Астразенека Аб TRIPLE-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2009014537A1 (en) 2007-07-25 2009-01-29 Hewlett-Packard Company Systems and methods for detecting ink mixing
WO2009100536A1 (en) 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
KR20120115237A (en) 2009-10-30 2012-10-17 어리어드 파마슈티칼스, 인코포레이티드 Methods and compositions for treating cancer
KR101663637B1 (en) 2009-11-13 2016-10-07 제노스코 Kinase inhibitors
KR20140047138A (en) 2011-08-04 2014-04-21 도쿠리츠교세이호진 고쿠리츠간켄큐센터 Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
US20130096136A1 (en) 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US10023855B2 (en) 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
EP2776420A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
SG11201500125QA (en) 2012-07-11 2015-02-27 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
EP2878672A4 (en) 2012-07-26 2016-02-17 Nat Cancer Ct Fusion gene of cep55 gene and ret gene
JP5759568B2 (en) 2012-09-25 2015-08-05 中外製薬株式会社 RET inhibitor
TWI629266B (en) 2012-12-28 2018-07-11 藍印藥品公司 Inhibitors of the fibroblast growth factor receptor
KR20150121712A (en) 2013-02-25 2015-10-29 브리스톨-마이어스 스큅 컴퍼니 C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
JP2016516026A (en) 2013-03-15 2016-06-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Pyridine derivatives as inhibitors of REARRANGE DDURING TRANSACTION (RET) kinase
WO2015006875A1 (en) 2013-07-18 2015-01-22 Methylgene Inc. Process for the preparation of substituted pyrimidines
WO2015025866A1 (en) 2013-08-20 2015-02-26 独立行政法人国立がん研究センター New fusion gene detected in lung cancer
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
AU2014337314B2 (en) 2013-10-17 2018-12-13 Blueprint Medicines Corporation Compositions useful for treating disorders related to KIT
US9434700B2 (en) 2013-10-25 2016-09-06 Neil Bifulco, JR. Inhibitors of the fibroblast growth factor receptor
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
JP6061341B2 (en) 2013-12-06 2017-01-18 朝日インテック株式会社 Guide wire
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
SG11201701694QA (en) 2014-09-10 2017-04-27 Glaxosmithkline Ip Dev Ltd Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
BR112017004897A2 (en) 2014-09-10 2017-12-12 Glaxosmithkline Ip Dev Ltd innovative compounds as rearranged inhibitors during transfection (ret)
US10221181B2 (en) 2014-11-14 2019-03-05 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
AU2016297754A1 (en) 2015-07-24 2018-02-15 Blueprint Medicines Corporation Compounds useful for treating disorders related to KIT and PDGFR
CA2995997A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
CN105255927B (en) 2015-09-30 2018-07-27 温州医科大学附属第一医院 A kind of KIAA1217-RET fusions
EP4331585A3 (en) 2015-11-02 2024-05-15 Blueprint Medicines Corporation Inhibitors of ret
CN108431008A (en) 2015-11-19 2018-08-21 蓝图药品公司 It can be used for treating the compound and composition with the relevant illnesss of NTRK
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
EP4285996A3 (en) 2016-04-15 2024-01-10 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039971A1 (en) * 2012-09-07 2014-03-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
WO2014072220A1 (en) * 2012-11-07 2014-05-15 Nerviano Medical Sciences S.R.L. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19, XP002675560, DOI: doi:10.1002/jps.2600660104
LUCA MOLOGNI ET AL: "RET kinase inhibitors: a review of recent patents (2012-2015)", EXPERT OPINION ON THERAPEUTIC PATENTS., vol. 27, no. 1, 26 September 2016 (2016-09-26), GB, pages 91 - 99, XP055373923, ISSN: 1354-3776, DOI: 10.1080/13543776.2017.1238073 *
WUTS; GREENE: "Protective Groups in Organic Synthesis", 2006, JOHN WILEY & SONS

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
US10774070B2 (en) 2015-02-06 2020-09-15 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
US11279688B2 (en) 2015-11-02 2022-03-22 Blueprint Medicines Corporation Inhibitors of RET
US10584114B2 (en) 2015-11-02 2020-03-10 Blueprint Medicines Corporation Inhibitors of RET
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018213329A1 (en) 2017-05-15 2018-11-22 Blueprint Medicines Corporation Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity
US11273160B2 (en) 2018-04-03 2022-03-15 Blueprint Medicines Corporation RET inhibitor for use in treating cancer having a RET alteration
US11963958B2 (en) 2018-04-03 2024-04-23 Rigel Pharmaceuticals, Inc. RET inhibitor for use in treating cancer having a RET alteration
US11872192B2 (en) 2018-04-03 2024-01-16 Blueprint Medicines Corporation RET inhibitor for use in treating cancer having a RET alteration
WO2020033838A2 (en) 2018-08-10 2020-02-13 Blueprint Medicines Corporation Treatment of egfr-mutant cancer
WO2020035065A1 (en) * 2018-08-17 2020-02-20 南京明德新药研发有限公司 Pyrazole derivative as ret inhibitor
CN112566907A (en) * 2018-08-17 2021-03-26 南京明德新药研发有限公司 Pyrazole derivatives as RET inhibitors
WO2020083311A1 (en) * 2018-10-24 2020-04-30 南京明德新药研发有限公司 Pyrazine derivative as ret inhibitor
CN111285875B (en) * 2018-12-06 2023-02-03 苏州信诺维医药科技股份有限公司 Heterocyclic compound, application thereof and pharmaceutical composition containing same
CN111285875A (en) * 2018-12-06 2020-06-16 苏州信诺维医药科技有限公司 Heterocyclic compound, application thereof and pharmaceutical composition containing same
CN111285882A (en) * 2018-12-07 2020-06-16 四川科伦博泰生物医药股份有限公司 Fused ring compound, pharmaceutical composition containing same, and preparation method and application thereof
CN111484479A (en) * 2019-01-25 2020-08-04 四川科伦博泰生物医药股份有限公司 Nitrogen heterocyclic compound, pharmaceutical composition containing nitrogen heterocyclic compound, preparation method and application of nitrogen heterocyclic compound
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2022529086A (en) * 2019-04-03 2022-06-16 広州白雲山医薬集団股分有限公司白雲山制薬総廠 Nitrogen-containing spiro ring derivative as a RET inhibitor
JP7198386B2 (en) 2019-04-03 2022-12-28 広州白雲山医薬集団股分有限公司白雲山制薬総廠 Nitrogen-containing spirocycle derivatives as RET inhibitors
CN113474345A (en) * 2019-04-03 2021-10-01 广州白云山医药集团股份有限公司白云山制药总厂 Nitrogen-containing spiro derivatives as RET inhibitors
WO2020200314A1 (en) * 2019-04-03 2020-10-08 南京明德新药研发有限公司 Nitrogen-containing spiro derivative as ret inhibitor
CN113474345B (en) * 2019-04-03 2023-04-18 广州白云山医药集团股份有限公司白云山制药总厂 Nitrogen-containing spiro derivatives as RET inhibitors
JP2022528437A (en) * 2019-04-12 2022-06-10 浙江海正薬業股▲ふん▼有限公司 Piperazine amide derivative, its manufacturing method and its use in medicine
JP7335972B2 (en) 2019-04-12 2023-08-30 浙江海正薬業股▲ふん▼有限公司 Piperazinamide derivatives, their preparation and their use in medicine
WO2020207419A1 (en) 2019-04-12 2020-10-15 浙江海正药业股份有限公司 Piperazine amide derivative, preparation method therefor, and use thereof in medicine
JP2022534067A (en) * 2019-05-20 2022-07-27 ティーワイケー メディシンズ インコーポレーテッド Compounds and their use as RET kinase inhibitors
CN113784963A (en) * 2019-05-20 2021-12-10 浙江同源康医药股份有限公司 Compounds useful as RET kinase inhibitors and uses thereof
CN113784963B (en) * 2019-05-20 2024-02-27 浙江同源康医药股份有限公司 Compounds useful as RET kinase inhibitors and uses thereof
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN113135896A (en) * 2020-01-18 2021-07-20 正大天晴药业集团股份有限公司 Methylpyrazole derivatives as RET inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023239422A2 (en) 2021-10-22 2023-12-14 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
WO2024022206A1 (en) * 2022-07-23 2024-02-01 浙江海正药业股份有限公司 Crystal form of piperazine amide derivative, preparation method therefor and use thereof

Also Published As

Publication number Publication date
UY37155A (en) 2017-10-31
AR107912A1 (en) 2018-06-28
US10183928B2 (en) 2019-01-22
US20170267661A1 (en) 2017-09-21
TW201738228A (en) 2017-11-01

Similar Documents

Publication Publication Date Title
US10183928B2 (en) Inhibitors of RET
US10035789B2 (en) Compounds useful for treating disorders related to RET
US10227329B2 (en) Compounds useful for treating disorders related to RET
JP7026196B2 (en) RET inhibitor
KR102134204B1 (en) New compounds
WO2016127074A1 (en) 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
EP2850082A1 (en) 2-amino, 6-phenyl substituted pyrido [2, 3 - d]pyrimidine derivatives useful as raf kinase inhibitors
WO2018183712A1 (en) Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
JP6139792B2 (en) Pyrido [2,3-d] pyrimidin-4-one compounds as tankyrase inhibitors
CN110461849B (en) CSF1R inhibitor and preparation method and application thereof
JP2022511236A (en) Substituted quinazolinone derivative, and its use as a positive allosteric regulator of mGluR4
JP2023538096A (en) Heteroaromatic ring compounds as RET kinase inhibitors and their production and use
CN114502556A (en) Biphenyl fluoro double bond derivative and preparation method and pharmaceutical application thereof
CN118772113A (en) Nitrogen-containing heterocyclic compounds as DNA polymerase Theta inhibitors
CN118221685A (en) Indoles as KRAS G12D inhibitors
CN118772141A (en) DNA polymerase Theta inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17714136

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17714136

Country of ref document: EP

Kind code of ref document: A1